# EDGAR Filing Document

**Accession Number:** 0001617765
**File Stem:** 0001062993-23-001003
**Filing Date:** 2023-1
**Character Count:** 166296
**Document Hash:** c40b9c001c19c3992151d898f2d34319
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-23-001003.hdr.sgml**: 20230117

**ACCESSION NUMBER**: 0001062993-23-001003

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 90

**CONFORMED PERIOD OF REPORT**: 20221130

**FILED AS OF DATE**: 20230117

**DATE AS OF CHANGE**: 20230117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Salona Global Medical Device Corp
- **CENTRAL INDEX KEY:** 0001617765
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0228

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-255642
- **FILM NUMBER:** 23532135

**BUSINESS ADDRESS:**
- **STREET 1:** 6160 INNOVATION WAY
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92009
- **BUSINESS PHONE:** 800-760-6826

**MAIL ADDRESS:**
- **STREET 1:** 6160 INNOVATION WAY
- **CITY:** CARLSBAD
- **STATE:** CA
- **ZIP:** 92009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INSPIRA FINANCIAL INC
- **DATE OF NAME CHANGE:** 20140825

?xml version="1.0" encoding="UTF-8"? Salona Global Medical Device Corp.: Form 10-Q - Filed by newsfilecorp.com

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended <u>**November 30, 2022**</u>

OR

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to

Commission File Number <u>**333-266806**</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **SALONA GLOBAL MEDICAL DEVICE CORPORATION** 

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **British Columbia** | **Not Applicable** |
| (I.R.S. Employer Identification Number) | (State or other jurisdiction of incorporation or organization) |
| **6160 Innovation Way, Carlsbad, California** | **92009** |
| (Address of principal executive offices) | Zip Code |

---

**(800) 760-6826**

(Registrant's telephone number, including area code)

------

Securities registered pursuant to Section 12(b) of the Act: <u>**None**</u>

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yes ☒ No ☐

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐ <br>Smaller reporting company ☒ Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

On January 13, 2022, 53,812,629 common shares, no par value, and 3,403,925 Class A shares, no par value, were outstanding.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**

---

| | | |
|:---|:---|:---|
| [**PART I. FINANCIAL INFORMATION**](#page3_integixAnchor) | [**PART I. FINANCIAL INFORMATION**](#page3_integixAnchor) | [2](#page3_integixAnchor) |
| [ITEM 1.](#page3_integixAnchor) | [Condensed Consolidated Financial Statements (Unaudited)](#page3_integixAnchor) | [3](#page3_integixAnchor) |
| [ITEM 2.](#page33_integixAnchor) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#page33_integixAnchor) | [33](#page33_integixAnchor) |
| [ITEM 3.](#page40_integixAnchor) | [Quantitative And Qualitative Disclosures About Market Risk](#page40_integixAnchor) | [39](#page40_integixAnchor) |
| [ITEM 4.](#page41_integixAnchor) | [Controls And Procedures](#page41_integixAnchor) | [40](#page41_integixAnchor) |
| **[**PART II OTHER INFORMATION**](#page41_integixAnchor)** | **[**PART II OTHER INFORMATION**](#page41_integixAnchor)** | [40](#page41_integixAnchor) |
| [ITEM 1.](#page41_integixAnchor) | [Legal Proceedings](#page41_integixAnchor) | [40](#page41_integixAnchor) |
| [ITEM 1A.](#page42_integixAnchor) | [Risk Factors](#page42_integixAnchor) | [41](#page42_integixAnchor) |
| [ITEM 2.](#page42_integixAnchor) | [Unregistered Sales of Equity Securities and Use of Proceeds](#page42_integixAnchor) | [41](#page42_integixAnchor) |
| [ITEM 6.](#page43_integixAnchor) | [Exhibits](#page43_integixAnchor) | [42](#page43_integixAnchor) |
| **[**SIGNATURE**](#page44_integixAnchor)** | **[**SIGNATURE**](#page44_integixAnchor)** | [43](#page44_integixAnchor) |

---

*As used in this Quarterly Report on Form 10-Q, the terms "the Company," "us," "our," the "Company" and "Salona" mean Salona Global Medical Device Corporation (a corporation incorporated under the laws of the Province of British Columbia formerly known as Brattle Street Investment Corp.) and its subsidiaries (unless the context indicates a different meaning).*

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**

**PART I. FINANCIAL INFORMATION** 

**Item 1. Condensed Consolidated Financial Statements (Unaudited)**

**For the Three and Nine Months Ended November 30, 2022, and November 30, 2021**

***(Expressed in Canadian Dollars, unless specified otherwise)***

---

| | |
|:---|:---|
| [Unaudited Interim Condensed Consolidated Balance Sheets](#page04_integixAnchor) | [3](#page04_integixAnchor) |
| [Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss](#page5_integixAnchor) | [4](#page5_integixAnchor) |
| [Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity](#page6_integixAnchor) | [5](#page6_integixAnchor) |
| [Unaudited Interim Condensed Consolidated Statements of Cash Flows](#page7_integixAnchor) | [6](#page7_integixAnchor) |
| [Notes to the Unaudited Interim Condensed Consolidated Financial Statements](#page8_integixAnchor) | [7](#page8_integixAnchor) |

---

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION** 

**Unaudited Interim Condensed Consolidated Balance Sheets**

**As at November 30, 2022, (unaudited) and February 28, 2022 (audited)**

*(In Canadian Dollars, unless specified otherwise)* 

---

| | | | |
|:---|:---|:---|:---|
|  | **Note** | **November 30,**<br>**2022** | **February**<br>**28, 2022** |
| **Assets** |  |  |  |
| Cash and cash equivalents | **19** | $3138860 | $8057100 |
| Accounts receivable, net | **5** | 7797115 | 6595668 |
| Inventories, net | **7** | 8590314 | 4969439 |
| Prepaid expenses and other receivables |  | 478808 | 412794 |
| **Total current assets** |  | **20005097** | **20035001** |
| Security deposit | **12** | 564694 | 484975 |
| Long-term accounts receivable | **5** | 191814 |  |
| Property and equipment, net | **8** | 3069273 | 1460175 |
| Right-of-use assets, net | **12** | 7878162 | 3941840 |
| Intangible assets, net | **9** | 9407662 | 6926582 |
| Goodwill | **4** | 12544397 | 9833039 |
| **Total assets** |  | $**53661099** | $**42681612** |
| **Liabilities and stockholders' equity** |  |  |  |
| **Liabilities** |  |  |  |
| Line of credit | **11** | $6162803 | $5497249 |
| Accounts payable and accrued liabilities | **10** | 6138923 | 3679396 |
| Current portion of debt | **11** | 193999 | 174361 |
| Current portion of lease liability | **12** | 814797 | 245257 |
| Other liabilities | **10** | 2066165 | 562262 |
| Obligation for payment of earn-out consideration | **4** | 13094513 | 12997846 |
| **Total current liabilities** |  | **28471200** | **23156371** |
| Debt, net of current portion | **11** | 587229 | 681758 |
| Lease liability, net of current portion | **12** | 6026697 | 3934431 |
| Deferred tax liability |  | 2425195 | 1755889 |
| **Total liabilities** |  | **37510321** | **29528449** |
| **Stockholders' equity** |  |  |  |
| Common stock; no par value, unlimited shares authorized; 53,707,780 shares issued and outstanding as of November 30, 2022 (February 28, 2022: 52,539,162) | **13** | 38767442 | 38046097 |
| Class A shares; no par value, unlimited shares authorized; 3,403,925 shares issued and outstanding as of November 30, 2022 (February 28, 2022: 1,355,425) | **13** | 1800064 | 480479 |
| Class A Shares to be issued: 19,019,000 Class A shares to be issued as of November 30, 2022 (February 28, 2022: nil) | **13** | 14264250 |  |
| Additional paid-in-capital | **13** | 8042404 | 6985107 |
| Accumulated other comprehensive income |  | 968394 | 1006361 |
| Deficit |  | (47691776) | (33364881) |
| **Total stockholders' equity** |  | **16150778** | **13153163** |
| **Total liabilities and stockholders' equity** |  | $**53661099** | $**42681612** |
| **Contingencies (Note 20)** |  |  |  |
| **Subsequent events (Note 21)** |  |  |  |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION** 

**Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss**

**For the three and nine months ended November 30, 2022, and 2021**

*(In Canadian Dollars, unless specified otherwise)*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | | **3 months ended** | **3 months ended** | **9 months ended** | **9 months ended** |
| | <br>**Note** | **November 30,**<br>**2022** | **November 30,**<br>**2021** | **November 30,**<br>**2022** | **November 30,**<br>**2021** |
| **Revenues** | **6** | $**10547652** | $**5286702** | $**30640439** | $**9850915** |
| **Cost of revenue** |  |  |  |  |  |
| Direct service personnel |  | 1472850 | 953260 | 4465024 | 1230443 |
| Direct material costs |  | 5269741 | 2431065 | 15146076 | 5306949 |
| Other direct costs |  | 309901 | 239741 | 863401 | 239741 |
| **Total cost of revenue** |  | **7052492** | **3624066** | **20474501** | **6777133** |
| **Gross margin** |  | **3495160** | **1662636** | **10165938** | **3073782** |
| **Operating expenses** |  |  |  |  |  |
| General and administrative | **17** | 4035814 | 1652592 | 10146960 | 3254217 |
| **Total operating expenses** |  | **4035814** | **1652592** | **10146960** | **3254217** |
| **Net (loss) income before the undernoted** |  | **(540654)** | **10044** | **18978** | **(180435)** |
| Amortization of intangible assets | **9** | (301990) | (165552) | (786842) | (244340) |
| Depreciation of property and equipment | **8** | (147622) | (65458) | (292476) | (131414) |
| Amortization of right-of-use assets | **12** | (285967) | (67817) | (508185) | (106700) |
| Interest expense |  | (226573) | (121518) | (508649) | (265602) |
| Foreign exchange loss |  | (13703) | (48934) | (13471) | (38397) |
| Gain on debt settlement |  |  |  |  | 15538 |
| Change in fair value of earn-out consideration | **4** |  |  | (2451600) |  |
| Change in fair value of contingent consideration | **4** | 980730 |  | (7532300) |  |
| Transaction costs including legal, financial, audit, US & Canadian regulatory expenses | **18,** | (1054602) | (1044455) | (2403285) | (2269923) |
| **Net loss before taxes** |  | **(1590381)** | **(1503690)** | **(14477830)** | **(3221273)** |
| Current income tax expense |  | (11754) | (7) | (41786) | (1995) |
| Deferred income tax recovery |  | 73538 | - | 192721 | - |
| **Net loss** |  | **(1528597)** | **(1503697)** | **(14326895)** | **(3223268)** |
| Other comprehensive loss |  |  |  |  |  |
| Foreign currency translation gain (loss) |  | (79919) | 112505 | (37967) | 128506 |
| **Comprehensive loss** |  | $**(1608516)** | $**(1391192)** | $**(14364862)** | $**(3094762)** |
| **Net loss per share** |  |  |  |  |  |
| Basic and diluted | **16** | $(0.03) | $(0.03) | $(0.26) | $(0.08) |
| Weighted average number of common shares outstanding |  | 55145538 | 44790162 | 54585045 | 41480296 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION** 

**Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity**

**For the three and nine months ended November 30, 2022, and 2021**

*(In Canadian Dollars, unless specified otherwise)*

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common stock** | **Common stock** | **Class A Shares** | **Class A Shares** | **Common stock to**<br>**be issued** | **Common stock to**<br>**be issued** | **Class A Shares to be**<br>**issued** | **Class A Shares to be**<br>**issued** | **Class A Shares to be**<br>**issued** | | | |
|  | <br>**Number** | <br>**Amount**<br>**$** | <br>**Number** | <br>**Amount**<br>**$** | **Number** | **Amount**<br>**$** | <br>**Number** | <br>**Amount $** | **Additional**<br>**paid-in-**<br>**capital**<br>**$** | <br>**Accumulated**<br>**other**<br>**comprehensive**<br>**income**<br>**$** | <br>**Deficit**<br>**$** | <br>**Total**<br>**$** |
| **Balance - August 31, 2021** | **44790162** | **36552873** | **1355425** | **480479** |  |  | **-** | **-** | **3895604** | **959321** | **(30712433**) | **11175844** |
| Stock based compensation |  |  |  |  |  |  |  |  | 292492 |  |  | 292492 |
| Foreign currency translation gain |  |  |  |  |  |  |  |  |  | 112505 |  | 112505 |
| Net loss for the period |  |  |  |  |  |  |  |  |  |  | (1503697) | (1503697) |
| **Balance - November 30, 2021** | **44790162** | **36552873** | **1355425** | **480479** | **-** | **-** | **-** | **-** | **4188096** | **1071826** | **(32216130)** | **10077144** |
| **Balance - February 28, 2021** | **33813308** | **31065513** | **-** | **-** |  |  | **-** | **-** | **3625762** | **943320** | **(28992862**) | **6641733** |
| Stock based compensation |  |  |  |  |  |  |  |  | 757792 |  |  | 757792 |
| Shares issued on exercise of options | 1605042 | 572350 |  |  |  |  |  |  | (195458) |  |  | 376892 |
| Shares exchanged to Class A Shares | (1355425) | (480479) | 1355425 | 480479 |  |  |  |  |  |  |  |  |
| Shares for debt settlement | 737000 | 94999 |  |  |  |  |  |  |  |  |  | 94999 |
| Shares issued on financing, net | 9990237 | 5300490 |  |  |  |  |  |  |  |  |  | 5300490 |
| Foreign currency translation<br>gain |  |  |  |  |  |  |  |  |  | 128506 |  | 128506 |
| Net loss for the period |  |  |  |  |  |  |  |  |  |  | (3223268) | (3223268) |
| **Balance - November 30, 2021** | **44790162** | **36552873** | **1355425** | **480479** | **-** | **-** | **-** | **-** | **4188096** | **1071826** | **(32216130)** | **10077144** |
| **Balance - August 31, 2022** | **53426054** | **38592772** | **1355425** | **480479** | 281726 | 174670 | **19019000** | **14264250** | **7661467** | **1048313** | **(46163179)** | **16058772** |
| Stock based compensation |  |  |  |  |  |  |  |  | 380937 |  |  | 380937 |
| Shares issued on financing, net | 281726 | 174670 |  |  | (281726) | (174670) |  |  |  |  |  |  |
| Shares issued related to the ALG agreement |  |  | 2048500 | 1319585 |  |  |  |  |  |  |  | 1319585 |
| Foreign currency translation loss |  |  |  |  |  |  |  |  |  | (79919) |  | (79919) |
| Net loss for the period |  |  |  |  |  |  |  |  |  |  | (1528597) | (1528597) |
| **Balance - November 30, 2022** | **53707780** | **38767442** | **3403925** | **1800064** | **-** | **-** | **19019000** | **14264250** | **8042404** | **968394** | **(47691776)** | **16150778** |
| **Balance - February 28, 2022** | **52539162** | **38046097** | **1355425** | **480479** |  |  | **-** | **-** | **6985107** | **1006361** | **(33364881)** | **13153163** |
| Stock based compensation |  |  |  |  |  |  |  |  | 1248709 |  |  | 1248709 |
| Shares issued on exercise of options | 28154 | 8426 |  |  |  |  |  |  | (3097) |  |  | 5329 |
| Shares issued on exercise of broker warrants | 454817 | 229598 |  |  |  |  |  |  | (13645) |  |  | 215953 |
| Shares for debt settlement | 260921 | 201401 |  |  |  |  |  |  |  |  |  | 201401 |
| Shares issued on financing, net | 281726 | 174670 |  |  |  |  |  |  | (174670) |  |  |  |
| Shares to be issued related to acquisition of SDP |  |  |  |  |  |  | 19162000 | 14371500 |  |  |  | 14371500 |
| Shares issued related to acquisition of SDP |  |  | 143000 | 107250 |  |  | (143000) | (107250) |  |  |  |  |
| Shares issued related to the ALG agreement |  |  | 2048500 | 1319585 |  |  |  |  |  |  |  | 1319585 |
| Class A Shares exchanged for common shares | 143000 | 107250 | (143000) | (107250) |  |  |  |  |  |  |  |  |
| Foreign currency translation loss |  |  |  |  |  |  |  |  |  | (37967) |  | (37967) |
| Net loss for the period |  |  |  |  |  |  |  |  |  |  | (14326895) | (14326895) |
| **Balance - November 30, 2022** | **53707780** | **38767442** | **3403925** | **1800064** | **-** | **-** | **19019000** | **14264250** | **8042404** | **968394** | **(47691776)** | **16150778** |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**

**Unaudited Interim Condensed Consolidated Statements of Cash Flows**

**For the nine months ended November 30, 2022, and 2021**

*(In Canadian Dollars, unless specified otherwise)*

---

| | | | |
|:---|:---|:---|:---|
|  |  | **November 30, 2022** | **November 30, 2021** |
| **Operating activities** | Note |  |  |
| Net loss |  | $(14326895) | $(3223268) |
| *Non-cash items:* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **8, 9, 12** | 1587503 | 482454 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest accretion on lease liability | **12** | 221776 | 146430 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock based compensation | **13** | 1248709 | 757792 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration | **4** | 7532300 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of earn-out consideration | **4** | 2451600 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of marketable securities |  |  | (6849) |
| &nbsp;&nbsp;&nbsp;&nbsp;Realized gain on sale of marketable securities |  |  | (10059) |
| *Changes in operating assets and liabilities:* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable |  | 491439 | (1065676) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other receivables |  | 104916 | 290101 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories |  | (1925755) | 408873 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities |  | 1390741 | 872727 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities |  | 1328423 | 11455 |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax liability |  | (192721) |  |
| **Net cash used in operating activities** |  | **(87964)** | **(1336020)** |
| **Investing activities** |  |  |  |
| Cash and restricted cash received on acquisition of SDP | **4** |  | 461321 |
| Cash received on acquisition of Mio-Guard | **4** | 3363 |  |
| Cash received on acquisition of Simbex | **4** |  | 632697 |
| Cash received on acquisition of DaMar | **4** | 199982 |  |
| Return of escrow |  |  | 215320 |
| Proceeds on sale of marketable securities |  |  | 496526 |
| Acquisition of Simbex | **4** |  | (5907079) |
| Acquisition of Mio-Guard | **4** | (589340) |  |
| Acquisition of DaMar | **4** | (4318235) |  |
| Acquisition of intellectual property and other intangibles | **9** | (278202) |  |
| Acquisition of property and equipment | **8** | (339588) | (41051) |
| **Net cash used in investing activities** |  | **(5322020)** | **(4142266**) |
| **Financing activities** |  |  |  |
| Repayment of long-term debt | **11** | (125552) | (2086324) |
| Proceeds from line of credit, net | **11** | 305284 | 898998 |
| Issuance costs | **13** |  | (124884) |
| Proceeds from exercise of stock options | **13** | 5329 | 376893 |
| Proceeds from exercise of broker warrants | **13** | 215953 |  |
| Net proceeds received from ALG agreement | **4** | 693365 |  |
| Lease payments | **12** | (533671) | (156750) |
| **Net cash provided by (used in) financing activities** |  | **560708** | **(1092067)** |
| Effect of foreign exchange rates on cash |  | (68964) | 191947 |
| Decrease in cash and cash equivalents and restricted cash |  | (4849276) | (6570353) |
| **Cash and cash equivalents and restricted cash, opening** |  | **8057100** | **12506142** |
| **Cash and cash equivalents and restricted cash, closing** |  | $**3138860** | $**6127736** |
| Supplementary |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest |  | $286873 | $265602 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes |  | 41786 | 1995 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issued for debt |  | 201401 | 94999 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash including the closing balance above |  |  | 487977 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**

**Notes to the Unaudited Interim Condensed Consolidated Financial Statements**

**For the three and nine months ended November 30, 2022, and 2021**

**(In Canadian Dollars, unless otherwise stated)**

------

**1. Description of the business**

Salona Global Medical Device Corporation (formerly known as Brattle Street Investment Corp.) ("the Company," "us," "our," "Salona," "Salona Global," or the "Company"), is a publicly traded company listed on the TSX Venture Exchange (the "Exchange" or "TSXV"). The Company is an acquisition oriented, US-based and revenue generating medical device technology company. The Company aims to leverage the liquid Canadian capital markets to acquire small to midsize US and internationally based medical device products and companies with the goal of expanding sales and improving operations. The Company's aim is to create a large, broad-based medical device company with global reach.

The Company was incorporated under the *Canada Business Corporations Act* on September 17, 2013. The Company's common shares trade on the Exchange under the symbol "SGMD". The Company's registered office is Suite 200E - 1515A Bayview Avenue, East York, Ontario, Ontario, M4G 3B5.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On December 21, 2020, the Company consolidated its issued and outstanding common shares based on 7.37 post-consolidation common shares for 10 pre-consolidation common shares (the "Consolidation"). These shares were retroactively restated on the consolidated statements of stockholders' equity.

On May 21, 2021, the Company acquired South Dakota Partners Inc. ("SDP").

On September 30, 2021, the Company acquired Simbex, LLC ("Simbex").

On November 28, 2021, the Company launched a new U.S. sales subsidiary called ALG Health Plus, LLC ("Health Plus"), aimed at selling medical devices and supplies to small, independent hospitals and group purchasing organizations, organizations that offer small medical offices and clinics access to devices and supplies on a larger scale creating efficiencies by aggregating purchasing volumes.

On March 11, 2022, the Company acquired Mio-Guard, LLC ("Mio-Guard").

On September 23, 2022, the Company successfully closed its acquisition of DaMar Plastics Manufacturing Inc. ("DaMar"), a company focused on designing, producing and selling specialty plastics in several markets including the medical device market.

With over 50 years in business, DaMar currently serves the medical and consumer industries with precision plastic molding technology. The acquisition builds upon the Company's strategy to create a fully integrated global medical device company and adds precision plastics technology capabilities to the Company.

Under the terms of the Purchase Agreement, the Company acquired DaMar through an indirect wholly owned subsidiary of the Company ("Salona Global Buyer") in exchange for US$3.2 million in cash and 1,576,609 common shares of the Salona Global Buyer, plus a contingent earn-out payment equal to 1.75 times EBITDA for the earn-out period, consisting of a combination of up to US$5.5 million in cash and up to 5,000,000 in shares of common stock of the Salona Global Buyer based on the performance of DaMar Plastics during the 12 month period ending February 28, 2024.

Pursuant to a Contribution and Exchange ‎Agreement, the sellers will be entitled ‎to exchange common shares of the Salona Global Buyer for Class "A" non-voting ‎common ‎shares of SGMD on a one-for-one basis‎‎.

On December 15, 2022, the Company announced its intention to focus on listing on the Nasdaq Capital Market ("Nasdaq") in 2023. As a first step, the Company has changed its fiscal year end to December 31, 2022, with the aim of preparing for a U.S. listing.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

The Company's operations could be significantly adversely affected by the effects of a widespread global outbreak of a contagious disease, including the recent outbreak of respiratory illness caused by COVID-19. The Company cannot accurately predict the impact COVID-19 will have on its operations and the ability of others to meet their obligations with the Company, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect the Company's operations and ability to finance its operations.

**2. Basis of presentation** 

The accompanying unaudited interim condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") and in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company's financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with U.S. GAAP were omitted pursuant to such rules and regulations.

The financial information contained in this report should be read in conjunction with the Company's Annual Report on Form 10-K for the fiscal year ended February 28, 2022, that the Company filed on May 31, 2022.

*Functional and presentation currency*

These unaudited interim condensed consolidated financial statements are expressed in Canadian dollars unless otherwise stated. The functional currency of the Company is Canadian dollars, and the functional currency of its operating subsidiaries Inspira Financial Company, Simbex, LLC, ALG Health Plus, LLC, Mio-Guard, SDP, DaMar, and its holding company subsidiaries noted below is US dollars.

**3. Significant accounting policies**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a) Basis of consolidation*

These statements consolidate the accounts of the Company and its wholly owned operating subsidiaries, namely, Simbex, LLC ("Simbex"), ALG Health Plus, LLC ("Health Plus"), South Dakota Partners Inc. ("SDP"), Inspira Financial Company, Mio-Guard, LLC ("Mio-Guard"), DaMar Plastics Manufacturing Inc. ("DaMar"), and 1077863 B.C., Ltd, in the United States. Additionally, these statements consolidate the Company's wholly owned holding company subsidiaries, namely, Pan Novus Hospital Sales Group, LLC, Brattle Acquisition I Corp., Simbex Acquisition Parent I Corporation, Simbex Acquisition Parent Corporation, Mio-Tech Parent LLC, and DaMar Acquisition Corporation. The Company owns 100% of all its subsidiaries. Intercompany balances and transactions are eliminated upon consolidation.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*b) Basis of measurement*

The unaudited interim condensed consolidated financial statements of the Company have been prepared on an historical cost basis except contingent consideration which are carried at fair value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*c) Use of estimates*

The preparation of unaudited interim condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies to useful lives of non-current assets, impairment of non-current assets, including goodwill and intangible assets, valuation of stock-based compensation, allowance for doubtful accounts, provisions for inventory and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company's estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*d) Operating segments*

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company's other components. The segment operating results are reviewed regularly by the Company's CEO to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available. As of November 30, 2022, the Company has one segment, healthcare operations, which includes production, design, development, and sale of medical devices to businesses in the United States. Assets, liabilities, revenues and expense from this segment are disclosed in the unaudited interim condensed consolidated balance sheets and statements of operations and comprehensive loss.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*e) Fair value of financial instruments*

The Company's financial instruments consist principally of cash and cash equivalents, accounts receivable, security deposit, accounts payable and accrued liabilities, line of credit, debt, contingent consideration payable, lease liabilities and other liabilities.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

Financial Accounting Standards Board ("FASB") Accounting Standards Codification (ASC) Topic 820, *Fair Value Measurements and Disclosures*, requires disclosure of the fair value of financial instruments held by the Company. FASB ASC Topic 825, *Financial Instruments*, defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures.

The carrying amounts reported in the interim unaudited condensed consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization, low risk of counterparty default and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:

---

| | |
|:---|:---|
| *Level 1 -* | Quoted prices in active markets for identical assets or liabilities. |
| *Level 2 -* | Inputs, other than Level 1, that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. |
| *Level 3 -* | Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. |

---

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.

As of November 30, 2022, and February 28, 2022, respectively, the Company did not identify any financial assets and liabilities other than contingent considerations resulting from the SDP, Simbex, ALG, DaMar, and Mio-Guard acquisitions, that would be required to be presented on the unaudited interim condensed consolidated balance sheet at fair value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*f) Revenue recognition*

Revenue comprises goods and services provided to the Company's contracted customers and sales-based royalties charged by the Company to licensees of the Intellectual Property (IP) developed by the Company.

In accordance with ASC 606 - *Revenue from Contracts with Customers,* the Company recognizes revenue upon the transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. The Company accounts for a customer contract when the rights of the parties, including the payment terms, are identified, the contract has commercial substance, collection of consideration is probable, and the contract has been signed and agreed to by both parties. Revenue is recognized when, or as, performance obligations are satisfied by transferring control or economic benefit of the service to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for its services. Revenue excludes sales tax and is recorded net of discounts and an allowance for estimated returns unless the terms of the sales are final.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

The principles in ASC 606 are applied using the following five steps:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Identify the contract with a customer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Identify the performance obligation(s) in the contract;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Determine the transaction price;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Allocate the transaction price to the performance obligation(s) in the contract; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Recognize revenue when (or as) the performance obligation(s) are satisfied.

SDP, Mio-Guard, DaMar, and Health Plus recognize revenue at a point-in-time upon transfer of control of goods to customers, which is generally upon shipment or delivery, depending on the delivery terms set forth in the customer contract, at an amount that reflects the consideration the Company received or expects to receive in exchange for the goods. Simbex recognizes its revenue over time as it meets its milestones and performs its obligations as agreed upon in its contracts with its customers. Payment received prior to the delivery of service is classified as deferred revenue.

For sales contracts with terms of more than one year, the Company recognizes any significant financing component as revenue over the contractual period using the effective interest method, and the associated interest income is reflected accordingly on the statement of operations and included in other income.

Provisions for discounts, returns and other adjustments are provided for in the period the related sales are recorded. The Company has concluded that it is the principal in its revenue arrangements because it controls the goods or services before transferring them to the customer.

The Company typically provides warranties for general repairs of defects that existed at the time of sale. These assurance-type warranties are accounted for as warranty provisions, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*g) Research and development costs*

Research and development costs are generally expensed as incurred. These costs primarily consist of personnel and related expenses and are classified as part of the general and administrative expenses on the unaudited interim condensed consolidated statements of operations and comprehensive loss.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*h) Cash and cash equivalents* 

Cash and cash equivalents comprise highly liquid interest-bearing securities that are readily convertible to cash and are subject to an insignificant risk of changes in value. The maturities of these securities as at the purchase date are 90 days or less. A variable amount of the cash is held in cash backed, liquid US money market funds with high institutional credit ratings. Most of these money market funds are placed in United States dollar and securities issued by the United States Government.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*i) Inventories*

Inventories are comprised of raw material, work-in-progress, trading goods, and finished goods, which consist principally of electrodes, electronic components, subassemblies, steel, hardware, and fasteners and are stated at the lower of cost (first-in, first-out) and net realizable value and include direct labor, materials, and other related costs. The Company periodically reviews inventory for evidence of slow-moving or obsolete items, and writes inventory down to net realizable value, as needed.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

This write-down is based on management's review of inventories on hand, compared to estimated future usage and sales, shelf-life assumptions, and assumptions about the likelihood of obsolescence. If actual market conditions are less favorable than those projected by the Company, additional write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*j) Goodwill*

Goodwill represents the excess of costs over fair value of net assets acquired from the Company's business combinations. Goodwill and intangible assets acquired in a business combination and determined to have an indefinite useful life are not amortized, but instead are tested for impairment at least annually in accordance with the FASB issued Accounting Standards Update ("ASU") No. 2017-04 *Intangibles-Goodwill and Other* (Topic 350). Because an assembled workforce cannot be sold or transferred separately from the other assets in the business, any value attributed to it is subsumed into goodwill. The Company evaluates the carrying value of goodwill annually and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying amount. Such circumstances could include, but are not limited to, (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator.

When evaluating whether the goodwill is impaired, the Company compares the fair value of the reporting unit to which the goodwill is assigned to its carrying amount, including goodwill. The Company identifies the reporting unit on a basis that is similar to its method for identifying operating segments as defined by the Segment Reporting Topic of the FASB ASC. If the carrying amount of a reporting unit exceeds its fair value, then the amount of the impairment loss must be measured. This evaluation is applied annually on each impairment testing date (December 31<sup>st</sup>) unless there is a triggering event present during an interim period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*k) Property and equipment*

Property and equipment are carried at cost less accumulated depreciation and impairment, if any. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation is computed using the straight-line method over the estimated useful lives of the assets as follows:

---

| | |
|:---|:---|
| Asset | Life |
| Machinery and equipment | 3 - 10 years |
| Computer equipment and software | 3 - 5 years |
| Furniture and fixtures | 7 - 10 years |
| Leasehold improvements | Over the lease period |
| Land improvements | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Over the lease period  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*l) Right-of-use asset*

The Company's right-of-use assets consist of leased assets recognized in accordance with ASC 842, *Leases* which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liability represents the Company's obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the unaudited interim condensed consolidated balance sheets and are expensed on a straight-line basis over the lease term in the unaudited interim condensed consolidated statement of operations and comprehensive loss. The Company determines the lease term by agreement with lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company's incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*m) Intangible assets*

Intangible assets consist of trademarks, intellectual property, customer base and non-competes (Note 4). Intangible assets with finite lives are amortized on a straight-line basis over their estimated useful lives and are measured at cost less accumulated amortization and accumulated impairment losses per the table below:

---

| | |
|:---|:---|
| Intangible asset | Life |
| Tradename - Trademarks | 5 years |
| Non-competes | 5 years |
| Intellectual Property | 5 years |
| Customer Base | 15 years |
| Other intangible assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Over life of asset  |

---

The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. The next assessment of useful lives is currently being performed as at December 31, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*n) Business Combination and Contingent consideration*

A business combination is a transaction or other event in which control over one or more businesses is obtained. A business is an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return in the form of dividends, lower costs or other economic benefits. A business consists of inputs and processes applied to those inputs that have the ability to create outputs that provide a return to the Company and its shareholders. A business need not include all of the inputs and processes that were used by the acquiree to produce outputs if the business can be integrated with the inputs and processes of the Company to continue to produce outputs. The Company considers several factors to determine whether the set of activities and assets is a business.

Business acquisitions are accounted for using the acquisition method whereby acquired assets and liabilities are recorded at fair value as of the date of acquisition with the excess of the purchase consideration over such fair value being recorded as goodwill and allocated to reporting units. If the fair value of the net assets acquired exceeds the purchase consideration, the difference is recognized immediately as a gain in the unaudited interim condensed consolidated statements of operations and comprehensive loss. Acquisition related costs are expensed during the period in which they are incurred, except for the cost of debt or equity instruments issued in relation to the acquisition which is included in the carrying amount of the related instrument. Certain fair values may be estimated at the acquisition date pending confirmation or completion of the valuation process. Where provisional values are used in accounting for a business combination, they are adjusted retrospectively in subsequent periods. However, the measurement period will not exceed one year from the acquisition date.

The determination of the value of goodwill and intangible assets arising from business combinations requires extensive use of accounting estimates and judgments to allocate the purchase price to the fair value of the net tangible and intangible assets acquired.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*o) Stock-Based Compensation*

The Company records stock-based compensation in accordance with FASB ASC Topic 718, *Compensation-Stock Compensation*. FASB ASC Topic 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the requisite service period. The Company recognizes in the unaudited interim condensed consolidated statements of operations and comprehensive loss the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*p) Basic and Diluted Earnings Per Share*

The Company has adopted the ASC 260-10 which provides for calculation of "basic" and "diluted" earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to stockholders by the weighted average number of common shares and Class A shares outstanding for the period. Except for voting rights, the Company's common stock and Class A shares have the same dividend rights, are equal in all respects, and are otherwise treated as if they were one class of shares, including the treatment for the earnings per share calculations. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive. There were no potentially dilutive shares outstanding as of November 30, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*q) Foreign Currency Transactions and Comprehensive Income*

U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company's subsidiaries is the US dollar. Translation gains (losses) are classified as an item of other comprehensive income in the stockholders' equity section of the unaudited interim condensed consolidated balance sheet.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*r) Income Taxes*

The Company accounts for income taxes in accordance with ASC Topic 740, *Income Taxes*, which requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company has not changed it methodology for estimating the valuation allowance. A change in valuation allowance affect earnings in the period the adjustments are made and could be significant due to the large valuation allowance currently established.

Under ASC 740, a tax position is recognized as a benefit only if it is 'more likely than not' that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the 'more likely than not' test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*s) Share purchase warrants*

The Company accounts for the share purchase warrants issued to investor and brokers pursuant to equity financing as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480, *Distinguishing Liabilities from Equity* and ASC 815, *Derivatives and Hedging*. The assessment considers whether the Warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the Warrants are indexed to the Company's own shares and whether the holders of the warrants could potentially require "net cash settlement" in a circumstance outside of the Company's control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of issuance of the Warrants and as of each subsequent reporting period end date while the warrants are outstanding. For issued investor warrants and broker warrants that meet all of the criteria for equity classification, such warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued investor warrants and broker warrants that do not meet all the criteria for equity classification, liability-classified warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of such warrants are recognized as a non-cash gain or loss on the unaudited interim condensed consolidated statements of operations and comprehensive loss.

For the period ended November 30, 2022, the Company concluded based on the above mentioned that the issued investor warrants and broker warrants met the criteria for equity classification in accordance with ASC 815-40 and therefore were classified under equity. The fair value of those warrants is determined by using Black Scholes valuation model on the date of issuance. Relative fair value method is applied to allocate gross proceeds from equity financing into its shares and warrants portion respectively. Those costs directly contributable to equity financing are accounted for as a reduction under stockholders' equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*t) Reclassification*

Certain prior year amounts have been reclassified for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*u) Recently issued pronouncements*

In September 2022, the FASB issued Accounting Standards Update (ASU) No. 2022-04 that requires additional qualitative and quantitative disclosures surrounding supplier finance programs intended to help investors better consider the effect of these programs on a company's working capital, liquidity, and cash flows over time. This update is effective for fiscal years beginning after December 15, 2022, including interim periods, except for the disclosure. Early adoption is permitted. The Company is currently evaluating the impact this update will have on its disclosures in future unaudited interim condensed consolidated Financial Statements.

In June 2022, the FASB issued ASU 2022-03 Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ("ASU 2022-03"), which (1) clarifies the guidance in ASC 820 on the fair value measurement of an equity security that is subject to a contractual sale restriction and (2) requires specific disclosures related to such an equity security. Under current guidance, stakeholders have observed diversity in practice related to whether contractual sale restrictions should be considered in the measurement of the fair value of equity securities that are subject to such restrictions. On the basis of interpretations of existing guidance and the current illustrative example in ASC 820-10-55-52 of a restriction on the sale of an equity instrument, some entities use a discount for contractual sale restrictions when measuring fair value, while others view the application of such a discount to be inconsistent with the principles of ASC 820. To reduce the diversity in practice and increase the comparability of reported financial information, ASU 2022-03 clarifies this guidance and amends the illustrative example. ASU No. 2022-03 is effective for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is in the process of determining the impact the adoption will have on its unaudited interim condensed consolidated financial statements as well as whether to early adopt the new guidance.

In March 2022, the FASB issued ASU No. 2022-02, Troubled Debt Restructurings and Vintage Disclosures. ASU 2022-02 eliminates the accounting guidance on troubled debt restructurings for creditors in ASC Topic 310 and amends the guidance on "vintage disclosures" to require disclosure of current-period gross write-offs by year of origination. ASU 2022-02 also updates the requirements related to accounting for credit losses under ASC Topic 326 and adds enhanced disclosures for creditors with respect to loan re-financings and restructurings for borrowers experiencing financial difficulty. ASU 2022-02 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is currently evaluating the extent of the impact of this ASU, but do not expect the adoption of this standard to have a significant impact on its unaudited condensed consolidated financial statements.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

In October 2021 FASB, issued ASU No. 2021-08, *Business Combinations* (Topic 805), *Accounting for Contract Assets and Contract Liabilities from Contracts with Customers*, which requires an entity (acquirer) to recognize and measure contract assets and liabilities acquired in a business combination in accordance with Topic 606. This update is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, with early adoption permitted. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company has elected to early adopt this standard. However, it did not have a material impact on the Company's unaudited interim condensed consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, *Financial Instruments - Credit Losses*, which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types of financial instruments will be estimated based on expected losses. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. This update is effective for annual periods beginning after January 1, 2023, as amended by ASU No. 2019-10, and interim periods within those periods, and early adoption is permitted. The Company is in the process of determining the impact the adoption will have on its unaudited interim condensed consolidated financial statements as well as whether to early adopt the new guidance.

In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes which amends ASC 740 Income Taxes (ASC 740). This update is intended to simplify accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and amending existing guidance to improve consistent application of ASC 740. This update is effective for fiscal years beginning after December 15, 2021. The guidance in this update has various elements, some of which are applied on a prospective basis and others on a retrospective basis with earlier application permitted. The adoption did not have a material impact on the Company's unaudited interim condensed consolidated financial statements and disclosures.

In May 2020, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815- 40): Issuer's Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This update provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. This update is effective for fiscal years beginning after December 15, 2021. The adoption did not have a material impact on the Company's unaudited interim condensed consolidated financial statements and disclosures.

In August 2020, the FASB issued guidance that simplifies the accounting for debt with conversion options, revises the criteria for applying the derivative scope exception for contracts in an entity's own equity, and improves the consistency for the calculation of earnings per share. The guidance is effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2021. The adoption did not have a material impact on the Company's unaudited interim condensed consolidated financial statements and disclosures.

In March 2020, the FASB issued ASU No. 2020-04 providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020, could be applied through December 31, 2022. In December 2022, the FASB issued No 2022-06 extending the sunset date of the relief provided under ASU No. 2020-04 to December 31, 2024. The ASU has not impacted the unaudited interim condensed consolidated financial statements. The Company has various contracts that reference LIBOR and is assessing how this standard may be applied to specific contract modifications through December 31, 2024.

Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying unaudited interim condensed consolidated financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.

**4. Acquisitions**

**South Dakota Partners Inc. ("SDP") Purchase Price**

The Company completed the purchase of all of the capital stock of South Dakota Partners Inc. (SDP), under the Purchase Agreement dated May 21, 2021. Under the Purchase Agreement, Salona acquired the manufacturer specializing in medical devices, full electronics box builds, printed circuit board assemblies, electrodes, drug delivery and many other products involving electronics, electro-mechanical assemblies, and various types of material conversion. The acquisition included all of the current customers, contract rights, inventory, equipment, workforce, and manufacturing infrastructure. At the time of the transaction, there were no material relationships between the seller and Salona or any of its affiliates, or any director or officer of Salona, or any associate of any such officer or director. As consideration, the Company will issue 19,162,000 non-voting class "A" shares of common stock valued at $12,340,570 subject to earn-out adjustments, including revenue shortfall adjustment and adjusted net assets adjustments. The Company assumed all of the assets and liabilities of SDP.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

In accordance with ASC 805 "Business Combinations" the measurement period for the acquisition is for one year during which the Company may re-evaluate the assets acquired, liabilities assumed and the goodwill resulting from the transaction as well as the change in amortization as a result of changes in the provisional amounts as if the accounting had been completed at the acquisition date.

The allocation of the purchase price to the assets acquired and liabilities assumed based on an estimate of fair values at the date of acquisition is as follows:

---

| | |
|:---|:---|
| Cash | $255 |
| Security deposit | 461066 |
| Accounts receivable | 2763621 |
| Inventories | 4958833 |
| Prepaid expenses | 21651 |
| Property and equipment | 1409421 |
| Right-of-use assets | 2343947 |
| Intangible assets | 2199444 |
| Goodwill | 9090357 |
| Accounts payable | (821244) |
| Accrued expenses | (201733) |
| Customer deposits | (221290) |
| Line of credit | (3732414) |
| Debt | (2971350) |
| Lease liability | (2498095) |
| Deferred tax liability | (557559) |
| Other liabilities | (163130) |
| **Total adjusted purchase price** | **12081780** |
| Goodwill | $9090357 |
| Tradename - Trademarks | 341929 |
| Intellectual Property | 320823 |
| Customer Base | 1266405 |
| Non-Competes | 270287 |
| **Total identifiable intangible assets including goodwill** | $**11289801** |

---

The table below summarizes the value of the total consideration given in the transaction:

---

| | |
|:---|:---|
| Stock (Parent Special Stock) | 12340570 |
| Floor Guarantee/Contingent Liability | 1139910 |
| Earn-out /Contingent Consideration (Revenue) | (21924) |
| Earn-out /Contingent Consideration (Net Assets) | (1376776) |
| **Total Consideration** | $**12081780** |

---

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

As of May 31, 2022, SDP has concluded its earn-out period and has met both the revenue and adjusted net asset threshold requirements to receive its full 19,162,000 non-voting "Class A" shares of common stock. As such, this obligation has been removed from the liability section of the unaudited interim condensed consolidated balance sheet as a contingent liability (as shown on the February 28, 2022, Consolidated Balance Sheet) and has been moved to the equity section as Share Capital. Please refer to the "Unaudited Interim Condensed Consolidated Statement of Stockholders' Equity" for more detail regarding this reclassification. As of May 31, 2022, the date of issuance, the fair value of the 19,162,000 shares was $14,371,500 (fair value as of February 28, 2022, was $11,919,900), of which 143,000 were issued at a value of $107,250. The change in fair value of $2,451,600 has been reflected as an expense on the unaudited interim condensed consolidated statements of operations and comprehensive loss.

**Assets Acquired from ALG-Health, LLC:**

On November 29, 2021, the Company consummated the acquisition of the customer lists, sales orders and supply agreements and related sales channel and intellectual property assets of ALG-Health, LLC ("ALG"), a business engaged in the selling medical devices and supplies to small, independent hospitals, group purchasing organizations, medical offices and clinics, in exchange for non-voting securities of Health Plus which are exchangeable for up to a maximum of 21,000,000 nonvoting Class A shares of the Company subject to the achievement of certain revenue and EBITDA targets. In connection with the transaction, our subsidiary ALG Health Plus entered into an exclusive supply agreement with ALG.

The contingent consideration liability represents potential future earnout payments to the Company that are contingent on Health Plus's and ALG's business arrangement achieving certain milestones. The fair value of the contingent consideration liability on November 29, 2021 and February 28, 2022, was estimated to be nil and as such, no contingent liability was recorded on the date of the agreement was executed. As of November 30, 2022, as a result of new arrangements, the fair value of the contingent consideration liability is estimated to be $298,183.

On November 21, 2022, 1,048,500 Class A shares were issued to two key individuals at ALG at a fair market price of $0.61 per share for achieving certain EBITDA milestones. On November 28, 2022, 1,000,000 Class A shares were issued to one key individual at ALG at a fair market price of $0.68 per share for achieving a revenue milestone as described in the agreement. $693,365 in cash was consideration for these shares.

**Simbex, LLC ("Simbex") Purchase Price:**

The Company completed the purchase of all the capital stock of Simbex, LLC (Simbex), under the Purchase Agreement dated September 30, 2021. Under the Purchase Agreement, Salona acquired the company which provides mechanical and electrical design and engineering services as well as consultancy services in the field of biomechanical systems and medical devices. The acquisition includes all its current customers, contract rights, work-in-process, equipment, workforce, as well as its consulting, design, and engineering infrastructure. At the time of the transaction, there were no material relationships between the seller and Salona or any of its affiliates, or any director or officer of Salona, or any associate of any such officer or director. As consideration, the Company provided $5,691,759 cash as well as issuing 6,383,954 shares of non-voting class "A" common stock valued at $6,769,769 subject to earn-out adjustments, including revenue shortfall adjustment and adjusted net assets adjustments. The Company assumed all the assets and liabilities of Simbex.

In accordance with ASC 805 "Business Combinations" the measurement period for the acquisition is for one year during which the Company may re-evaluate the assets acquired, liabilities assumed and the goodwill resulting from the transaction as well as the change in amortization as a result of changes in the provisional amounts as if the accounting had been completed at the acquisition date.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

The allocation of the purchase price to the assets acquired and liabilities assumed based on an estimate of fair values at the date of acquisition as follows:

---

| | |
|:---|:---|
| Cash | $632697 |
| Accounts Receivable | 1402315 |
| Work-in-process | 301180 |
| Prepaid expenses | 34992 |
| Property and equipment | 122916 |
| Other receivables | 6395 |
| Intangible Assets | 5175486 |
| Goodwill | 6263204 |
| Accounts payable and accrued liabilities | (33560) |
| Accrued expenses | (1095) |
| Unearned revenue | (131016) |
| Deferred tax liability | (1311986) |
| **Total adjusted purchase price** | $**12461528** |

---

The amount allocated to identifiable intangible assets was determined by the Company's management. Other intangible assets are being amortized over their useful life in accordance with the guidance contained in the FASB issued ASC Topic 350 "Goodwill and Other Intangible Assets". As of November 30, 2022, Management estimates that the amount of goodwill that will be deductible for income tax purposes for the year ending December 31, 2022, is $434,918.

---

| | |
|:---|:---|
| Goodwill | $6263204 |
| Tradename - Trademarks | 933865 |
| Customer Base | 3648148 |
| Non-Competes | 593473 |
| **Total identifiable intangible assets including goodwill** | $**11438690** |

---

The table below summarizes the value of the total consideration given in the transaction:

---

| | |
|:---|:---|
| Cash | $4428900 |
| Working Capital Adjustment | 1262859 |
| Value of Escrowed Stock | 126540 |
| Value of Earnout / Contingent Consideration | 6643229 |
| **Total Consideration** | $**12461528** |

---

The Working Capital Adjustment comprises:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● the closing cash payment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● the closing escrowed stock valued at US$100,000, valued at the 30-day Volume Weighted Average Price ("VWAP") determined as of the closing date;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● pro-rata bonuses to be paid to employees for 2021; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;● ordinary course bonuses for 2022.

The contingent consideration liability represents potential future earnout payments to the Company that are contingent on Simbex's business achieving certain milestones. The fair value of the contingent consideration liability of $6,769,769 was recognized on the acquisition date and was measured using unobservable (Level 3) inputs. As of November 30, 2022, the fair value of the contingent consideration liability is $7,299,311 (February 28, 2022, $1,077,948) using risk free rate of 4% and volatility of 31.9%. The $6,221,363 increase in the contingent consideration liability from February 28, 2022, has been taken as an expense on the unaudited interim condensed consolidated statements of operations and comprehensive loss.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

On February 28, 2022, the Company updated its assessment of the fair value of goodwill from the Simbex LLC acquisition, in conjunction with the Company's third-party valuation experts based on updated year to date results of the acquired entity, intangible assets, and other factors resulting in an impairment to goodwill of $5,520,522. The fair value of goodwill was calculated by estimating the present value of future cash flows adjusted for redundant assets, working capital, and cost of disposal. The impairment of goodwill and adjustments to contingent consideration represent management's best estimates. Contingent consideration remains an estimate until the consideration is paid in line with the previously published purchase agreements relating to the Company's acquisitions. Goodwill represents an estimate of future value of the business based on acquisition data and always represents management's best estimate due to the variable nature of future performance

**Mio-Guard LLC ("Mio-Guard")**

On March 11, 2022, the Company acquired 100% units of Mio-Guard for a consideration which comprised of $589,340 of cash and Salona stock at closing, and on future periods on an earnout basis.

In accordance with ASC 805 "Business Combinations" the measurement period for the acquisition is for one year during which the Company may re-evaluate the assets acquired, liabilities assumed and the goodwill resulting from the transaction as well as the change in amortization as a result of changes in the provisional amounts as if the accounting had been completed at the acquisition date.

The table below summarizes the value of the total consideration given in the transaction:

---

| | |
|:---|:---|
| At closing (1,300,000 Class B units) | $702000 |
| Quarterly Earnout payments (Maximum of 2,700,000 Class B Units) | 1166464 |
| **Total Consideration** | $**1868464** |

---

The business combination accounting is not yet complete, and the amounts assigned to assets acquired and liabilities assumed are provisional. Therefore, this may result in future adjustments to the provisional amounts as information is obtained about facts and circumstances that existed at the acquisition date. A summary of the preliminary purchase price allocation at fair value is below.

---

| | |
|:---|:---|
| Cash | $3363 |
| Accounts receivable | 531601 |
| Inventory | 498897 |
| Property and equipment | 73445 |
| Right-of-use assets | 471926 |
| Intangible assets and goodwill | 1732602 |
| Accounts payable | (764225) |
| Due to related parties | (2307) |
| Lease liability | (471926) |
| Deferred tax liability | (204912) |
| **Total adjusted purchase price** | $**1868464** |

---

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

The amount allocated to identifiable intangible assets was determined by the Company's management. Other intangible assets are being amortized over their useful life in accordance with the guidance contained in the FASB issued ASC Topic 350 "Goodwill and Other Intangible Assets".

---

| | |
|:---|:---|
| Goodwill (including workforce) | $721387 |
| Tradename | 220056 |
| Customer Relationships | 532968 |
| Non-Competes | 49609 |
| Other intangible assets | 208582 |
| **Total identifiable intangible assets including goodwill** | $**1732602** |

---

The contingent consideration liability represents potential future earnout payments to the Company that are contingent on Mio-Guard's business achieving certain milestones. The fair value of the contingent consideration liability of $1,166,465 was recognized on the acquisition date and was measured using unobservable (Level 3) inputs. As of November 30, 2022, the fair value of the contingent consideration liability is $1,813,674 using risk free rate of 4% and volatility of 31.85%. The change in the fair value of the contingent consideration liability from the date of acquisition, has been taken as an expense on the unaudited interim condensed consolidated statements of operations and comprehensive loss.

Since acquisition, Mio-Guard has generated $5,198,062 of revenue and has generated net earnings before tax of $281,357. These amounts are included in the unaudited interim condensed consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, Mio-Guard's revenue would have been $5,263,365 and profit before tax would have been $250,381. If the combination had taken place at the beginning of the year, consolidated revenues would have been $35,903,804 and consolidated losses before tax would have been ($14,227,449). The pro forma unaudited results include estimates and assumptions which management believes are reasonable. These assumptions include an adjustment to operating income for one-time transactional costs that would not have occurred without the acquisition of Mio-Guard. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.

**DaMar Plastics Manufacturing, Inc. ("DaMar")**

On September 23, 2022, the Company acquired 100% of the shares of DaMar for a consideration which comprised of cash, and special parent stock at closing, and future contingent consideration during the earnout period.

In accordance with ASC 805 "Business Combinations" the measurement period for the acquisition is for one year during which the Company may re-evaluate the assets acquired, liabilities assumed and the goodwill resulting from the transaction as well as the change in amortization as a result of changes in the provisional amounts as if the accounting had been completed at the acquisition date.

The table below summarizes the value of the total consideration given in the transaction:

---

| | |
|:---|:---|
| Cash | $4071000 |
| Working capital adjustment | 247235 |
| Stock (in Salona Global Buyer exchangeable for Class A shares in the Company) | 967650 |
| Value of earnout/contingent consideration | 2656636 |
| **Total Consideration** | $**7942521** |

---

The business combination accounting is not yet complete, and the amounts assigned to assets acquired and liabilities assumed are provisional. Therefore, this may result in future adjustments to the provisional amounts as information is obtained about facts and circumstances that existed at the acquisition date. A summary of the preliminary purchase price allocation at fair value is below.

---

| | |
|:---|:---|
| Cash | $199982 |
| Accounts receivable | 731640 |
| Inventory | 791552 |
| Property and equipment | 1390121 |
| Right-of-use assets | 3061590 |
| Prepaid and other | 158696 |
| Intangible assets and goodwill | 3968476 |
| Accounts payable and other assumed liabilities | (177232) |
| Other liabilities | (3972) |
| Unearned revenues | (104401) |
| Lease liability | (1568820) |
| Deferred tax liability | (505111) |
| **Total adjusted purchase price** | $**7942521** |

---

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

The amount allocated to identifiable intangible assets was determined by the Company's management. Other intangible assets are being amortized over their useful life in accordance with the guidance contained in the FASB issued ASC Topic 350 "Goodwill and Other Intangible Assets".

---

| | |
|:---|:---|
| Goodwill (including workforce) | $1989970 |
| Tradename | 169625 |
| Customer Relationships | 1290507 |
| Non-Competes | 518374 |
| **Total identifiable intangible assets including goodwill** | $**3968476** |

---

The contingent consideration liability represents potential future earnout payments to the Company that are contingent on DaMar's business achieving certain milestones. The fair value of the contingent consideration liability of $3,624,286 was recognized on the acquisition date and was measured using unobservable (Level 3) inputs. As of November 30, 2022, the fair value of the contingent consideration liability is $3,683,345 using risk free rate of 3.5% and volatility of 60.0%. The change in the fair value of the contingent consideration liability from the date of acquisition, has been taken as income on the unaudited interim condensed consolidated statements of operations and comprehensive loss.

Since acquisition, DaMar has generated $1,528,558 of revenue and has generated net earnings before tax of $220,403. These amounts are included in the unaudited interim condensed consolidated statements of operations and comprehensive loss. If the combination had taken place at the beginning of the year, DaMar's revenue would have been $5,816,513 and profit before tax would have been $1,092,984. If the combination had taken place at the beginning of the year, consolidated revenues would have been $36,456,952 and consolidated losses before tax would have been ($13,384,846). The pro forma unaudited results include estimates and assumptions which management believes are reasonable. These assumptions include an adjustment to operating income for one-time transactional costs that would not have occurred without the acquisition of DaMar. Additionally, the pro forma results do not include any cost savings or other effects of the planned integration of these entities and may not be fully indicative of the results that would have occurred if the business combination had been in effect on the dates indicated.

**5. Accounts receivable**

---

| | | |
|:---|:---|:---|
|  | **November 30, 2022** | **February 28, 2022** |
| Trade accounts receivable | $7870261 | $6416055 |
| Allowance for doubtful accounts | (73146) | (54150) |
| Other receivables |  | 233763 |
| Long-term accounts receivable | 191814 |  |
| **Total accounts receivable** | $**7988929** | $**6595668** |

---

During the quarter ended, November 30, 2022, SDP had four customers accounting for 89% (February 28, 2022 - two customers accounting for 78%) of revenues and as of November 30, 2022, those four customers accounted for 93% (February 28, 2022, 84%) of accounts receivable, which is a material concentration of risks. During the three and nine months ended November 30, 2022, SDP's revenue makes up 45% and 49% of total revenues respectively.

During the quarter ended November 30, 2022, Simbex had four customers accounting for 73% (February 28, 2022, three customers accounting for 52%) of revenues. Additionally, as of November 30, 2022, Simbex had five customers which accounted for 69% (February 28, 2022, four customers accounted for 74%) of accounts receivable. During the three and nine months ended November 30, 2022, Simbex's revenue makes up 26% and 27% of total revenues respectively.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

**6. Disaggregation of Revenues**

During the three and nine months ended November 30, 2022, $7,849,808 and $22,151,414 of the sales revenue was earned from "point-in-time" revenue respectively ($3,615,905 and $8,118,882 for the three and nine months ended November 30, 2021, respectively) and $2,697,844 and $8,489,025 of the sales revenue was earned "over-a-period" of time respectively ($1,732,033 and $1,732,033 for the three and nine months ended November 30, 2021, respectively).

**7. Inventories**

The Company tracks inventory for manufactured goods as it progresses through the production process. The Company allocates inventory into four major buckets: Raw material, work in progress, trading goods, and finished goods. Purchased finished goods are classified as trading goods.

---

| | | |
|:---|:---|:---|
|  | **November 30, 2022** | **February 28, 2022** |
| Raw materials | $6660573 | $4640896 |
| Work in progress | 995060 | 259235 |
| Finished goods | 268544 | 69308 |
| Trading goods | 666137 |  |
| **Total** | $**8590314** | $**4969439** |

---

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

**8. Property and equipment**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Cost** | **February**<br>**28, 2022** | **Acquired**<br>**March**<br>**11, 2022,<br>and September<br>23, 2022** | **Total** | **Additions** |  | **Translation** | **November 30,**<br>**2022** |
| Machinery and equipment | $1444616 | $1387142 | $2831758 | $157698 | $– $| 90770 | $3080226 |
| Computer equipment and software | 73728 | 45848 | 119576 | 135906 | – | 10087 | 265569 |
| Furniture and fixtures | 10235 | 27598 | 37833 | 22597 | – | 3072 | 63502 |
| Land improvements |  |  |  | 23387 | – | 734 | 24121 |
| Leasehold improvements | 134516 | 2979 | 137495 |  | – | 8567 | 146062 |
| Total | $1663095 | $1463567 | $3126662 | $339588 | $– $| 113230 | $3579480 |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Accumulated Depreciation** | **February**<br>**28, 2022** | **Acquired**<br>**March**<br>**11, 2022**<br>**and September** <br>**23, 2022** | **Total** | **Additions** | **Disposal** | **Translation** | **November 30,**<br>**2022** |
| Machinery and equipment | $178244 | $- | $178244 | $256448 | $- | $12103 | $446795 |
| Computer equipment and software | 15269 |  | 15269 | 19789 |  | 1596 | 36654 |
| Furniture and fixtures | 1292 |  | 1292 | 2201 |  | 151 | 3644 |
| Land improvements |  |  |  | 876 |  | 29 | 905 |
| Leasehold improvements | 8115 |  | 8115 | 13162 |  | 932 | 22209 |
| Total | $202920 | $- | $202920 | $292476 | $- | $14811 | $510207 |
| **Net Book Value** | $**1460175** |  |  |  |  |  | $**3069273** |

---

**9. Intangible assets**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Cost** | **February**<br>**28, 2022** | **Acquired**<br>**March**<br>**11, 2022**<br>**and September**<br>**23, 2022** | **Total** | **Additions** |  | **November 30,**<br>**2022** |
| Tradename-Trademarks | $1275794 | $389681 | $1665475 | $- | $– $| 1665475 |
| Intellectual Property | 320823 |  | 320823 | 242284 | – | 563107 |
| Customer Base | 4914553 | 1823475 | 6738028 |  | – | 6738028 |
| Non-Competes | 863760 | 567982 | 1431742 |  | – | 1431742 |
| Other Intangible Assets |  | 208582 | 208582 | 35918 | – | 244500 |
| Total | $7374930 | $2989720 | $10364650 | $278202 | $– $| 10642852 |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Accumulated depreciation** | **February**<br>**28, 2022** | **Acquired**<br>**March**<br>**11, 2022**<br>**and September**<br>**23, 2022** | **Total** | **Additions** | **Disposal** | **November 30,**<br>**2022** |
| Tradename-Trademarks | $133260 | $- | $133260 | $240745 | $- | $374005 |
| Intellectual Property | 51968 |  | 51968 | 80901 |  | 132869 |
| Customer Base | 169783 |  | 169783 | 301423 |  | 471206 |
| Non-Competes | 93337 |  | 93337 | 163773 |  | 257110 |
| Other Intangible Assets |  |  |  |  |  |  |
| Total | $448348 | $- | $448348 | $786842 | $- | $1235190 |
| **Net Book Value** | $**6926582** |  |  |  |  | $**9407662** |

---

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

&nbsp;&nbsp;&nbsp;&nbsp;**10. Accounts payable and accrued liabilities**

---

| | | |
|:---|:---|:---|
|  | **November 30,**<br>**2022** | **February 28,**<br>**2022** |
| Accounts payable | $3723112 | $2862694 |
| Accrued liabilities | 2415811 | 816702 |
| Other liabilities | 2066165 | 562262 |
| **Total** | $**8205088** | $**4241658** |

---

Other liabilities include unearned customer deposits and unearned revenues totaling $1,547,639 (February 28, 2022, $426,609).

**11. Line of credit and debt**

The line of credit facility is with a financial institution whereby the Company, through SDP, may borrow up to US$5,400,000 with a maturity on August 1, 2023. Borrowings' bear interest at 4% or prime +0.75% per annum, whichever is greater, and any accrued unpaid interest is due on a monthly basis. The balance is secured by its entire $7,113,721 (US $5,266,303) of inventory and $4,136,888 (US $3,062,547) of accounts receivable of SDP and not the Parent or any other subsidiary. As of November 30, 2022, the balance outstanding under the agreement was $6,162,804 (US $4,562,336) (February 28, 2022 - $5,497,249 (US$4,329,224).

In accordance with the agreement, the Company is subject to a financial covenant. The balance of the line of credit may not exceed the lesser of US $5,400,000 or the sum of 90% of accounts receivable, 50% of raw materials, 60% of finished inventory (up to US $2,500,000) and an amortizing borrowing base of $400,000 (which shall be reduced $16,667 each month), which must be met on a monthly basis. Additionally, the Company cannot make any loans, advances, or intercompany transfers of cash flow at any time. Since the execution of the debt line on June 9, 2021, to November 30, 2022, the Company was in compliance with the financial covenant.

**Debt**

---

| | |
|:---|:---|
|  | **Crestmark**<br>**term loan** |
| **Balance, February 28, 2022** | $856119 |
| Additions |  |
| Principal repayments | (125552) |
| Translation | 50661 |
| **Balance, November 30, 2022** | 781228 |
| Less: current portion | (193999) |
| Long-term portion | $587229 |

---

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

As of November 30, 2022, the Company's total debt is $781,228 (February 28, 2022 - $856,119), of which $193,999 is considered current (February 28, 2022, $174,361) and $587,229 is considered long-term (February 28, 2022 $681,758).

*Term Note*

On June 9, 2021, the Company borrowed $982,200 (US$750,000) with a financial institution, Crestmark. The loan is secured by a loan and security agreement and may not exceed 92% of the net book value of SDP's machinery and equipment, which on November 30, 2022, was $1,427,000. The debt accrues interest at 2.75% in excess of Wall Street Journal Prime rate with a minimum of 6% per annum with monthly payments of principal and interest in the amount of $18,990 (US$14,500) beginning on the first day of the first full month following the initial funding and maturing on June 1, 2024. As of November 30, 2022, the balance of the note was $781,228 (US$578,345).

**12. Leases**

Set out below are the carrying amount of right of use assets and the movements during the nine months ended November 30, 2022:

---

| | |
|:---|:---|
|  | **Right-of-use assets** |
| **Balance, February 28, 2022** | $**3941840** |
| Acquired | 4001998 |
| Amortization | (508185) |
| Impact of modification | 180130 |
| Translation | 262379 |
| **Balance, November 30, 2022** | $**7878162** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Lease liability** | **Current** | **Long-term** |
| **Balance, February 28, 2022** | $**4179688** | $**245257** | $**3934431** |
| Acquired | 2504196 |  |  |
| Interest lease expense | 221776 |  |  |
| Lease payments | (533671) |  |  |
| Impact of modification | 180130 |  |  |
| Translation | 289375 |  |  |
| **Balance, **November 30** **, 2022** | $**6841494** | $**814797** | $**6026697** |

---

Future minimum lease payments payable are as follows:

---

| | |
|:---|:---|
| Twelve months ending November 30, 2023 | $1211499 |
| Twelve months ending November 30, 2024 | 1264889 |
| Twelve months ending November 30, 2025 | 1309183 |
| Twelve months ending November 30, 2026 | 1136929 |
| Twelve months ending November 30, 2027 | 611585 |
| 2028 and thereafter | 3609138 |
| Total future minimum lease payments | 9143223 |
| Less: Interest on lease liabilities | (2301729) |
| Total present value of minimum lease payments | 6841494 |
| Less: current portion | 814797 |
| **Non-current portion** | $**6026697** |

---

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

On November 30, 2022, the weighted average remaining lease terms were 9.40 years (February 28, 2022 - 13.3 years) and the weighted average discount rate was 6.14% (February 28, 2022 - 5.46%).

In October 2018, SDP sold its facility in Clear Lake, South Dakota for $2,858,248 (US$2,182,461). In connection with the sale, SDP entered into a lease agreement for the facility with an initial lease term of 15 years for a base annual rent of $250,096 (US$190,965), with four extension options of five years each. The base rental amount increases annually on the first day of the lease year at the lesser of 2% or 1.25 times the change in the price index, as defined. Per the lease agreement, the Company delivered a letter of credit in the amount of $515,911 (US$381,930), to be renewed annually for the duration of the lease agreement. The letter of credit is secured by a guaranteed investment certificate, which is recorded as security deposit on the unaudited interim condensed consolidated balance sheet.

On October 1, 2021, Simbex entered into a lease agreement for an office space located in Lebanon, NH with an initial lease term of 3 years for a base annual rent of $206,190 (US$157,440), with an option to extend for five years. The base rental amount increases annually on the first day of the lease year based on the change in the rolling average of the cost-of-living index for the prior six reporting periods. Per the lease agreement, the Company is also responsible to pay a prorated share of the building overhead monthly as additional rent. The annual amount for this additional rent is $122,338 (US $93,413).

On April 1, 2022, Inspira Financial Company entered into a lease agreement for an office space located in Encino, CA with a lease term of 6 months for a base annual rent of $25,350 (US$19,752), with extension options of 6 months each. The base rental amount increases annually on a case-by-case basis. The Company has elected the practical expedient permitted under ASC 842 not to account, as insignificant. Inspira Financial Company terminated this lease of September 30, 2022.

On September 21, 2022, Inspira Financial Company entered into a lease agreement for its corporate headquarters and distribution center located in Carlsbad, CA for a base annual rent of $104,955 (US $80,140). The lease began on October 1, 2022, with an initial lease term of 4 years and 2 months, which will end on November 30, 2026. The initial lease agreement includes an option to renew for an additional 5 years. The base rental amount increases annually as per the base rent schedule included in the lease agreement.

On January 1, 2022, Mio-Guard LLC entered into a lease agreement for an office space located in Holt, MI with an initial lease term of 5 years for a base annual rent of $112,179 (US$85,656). The base rental amount increases annually on the first day of the lease year at the lesser of 2.27% or 1.25 times the change in the price index, as defined.

On July 1, 2012, DaMar entered into a lease agreement for an industrial and office space located in El Cajon, CA with an initial lease term of 7 years. The lease was automatically extended for an additional 7 years on July 1, 2019, for a base annual rent of $429,605 (US$328,032). The lease is currently set to terminate on June 30, 2026. The base rental amount increases annually on the first day of the lease year by 3% of the proceeding month's lease payment as defined in the agreement.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

**13. Stockholders' Equity** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*a. Share capital*

Unlimited voting common shares without par value

Unlimited non-voting convertible Class A shares without par value

*Issuances*

As of November 30, 2022, and February 28, 2022, the Company had 53,707,780 and 52,539,162 common shares outstanding, respectively, with a value of $38,767,442 and $38,046,097, respectively.

As of November 30, 2022, and February 28, 2022, the Company had 3,403,925 and 1,355,425 Class A shares outstanding, respectively, with a value of $1,800,064 and $480,479, respectively.

On May 4, 2022, 454,817 shares of common stock were issued on the exercise of 454,817 broker share purchase warrants at an exercise price of $0.4749 per share. Proceeds received from this exercise totaled $215,953.

On May 25, 2022, 28,154 shares of common stock were issued on the exercise of 28,154 stock options at an exercise price of $0.19 per share. Proceeds received from this exercise totaled $5,329.

On May 31, 2022, 143,000 Class A shares were issued to former owner of SDP at a fair market price of $0.75 per share These shares were issued upon completion of SDP's earn-out period. No cash was required to be received as consideration for these shares. Immediately following the issuance, the 143,000 Class A shares were exchanged for 143,000 common shares of the Company.

On July 22, 2022, the Company entered into a share for debt agreement, pursuant to which it issued an aggregate of 260,921 shares of common stock in satisfaction of $201,401 (US$156,553) of indebtedness owed to a service provider. The 260,921 shares of common stock were valued at $201,401 (US $156,553) based on a share price on the date of issuance.

In connection with the closing of the February 15, 2022 Private Offering, the Company entered into a Registration Rights Agreement with the purchasers and the Underwriters (the "Registration Rights Agreement") providing for the filing of a registration statement (the "Registration Statement") with the Securities and Exchange Commission registering the resale of the common shares issued and issuable in connection with the Private Offering (collectively, the "Securities"). Under the Registration Rights Agreement, the Company was obligated to file the Registration Statement no later than April 1, 2022, and to use commercially reasonable efforts to cause the Registration Statement to be declared effective no later than 180 days after February 15, 2022. As a result of the Company's delay in filing and causing the Registration Statement to become effective timely, the liquidated damages to the purchasers and the Underwriters was an aggregate amount of 281,726 additional common shares. On September 14, 2022, these 281,726 common shares were issued for a fair value of $174,670.

In connection with the acquisition of ALG Health's customer lists, sales orders and supply agreements and related sales channel and intellectual property assets on November 21, 2021, Class A shares are to be issued based on achieving certain EBITDA and revenue milestones. On November 21, 2022, 1,048,500 Class A shares were issued to two key individuals at ALG at a fair market price of $0.61 per share for achieving certain EBITDA milestones. No cash was required to be received as consideration for these shares. On November 28, 2022, 1,000,000 Class A shares were issued to one key individual at ALG at a fair market price of $0.68 per share for achieving a revenue milestone as described in the agreement. $693,365 in cash was consideration for these shares.

*Shares to be issued*

On May 31, 2022, SDP has concluded its earn-out period and achieved its milestones allowing SDP to receive its full earn-out compensation of 19,162,000 Class A shares (as described in detail in Note 4). These shares will be allocated to the previous owners of SDP based on their percentage of ownership on the date of sale. As of May 31, 2022, the fair value of the shares to be issued is $14,371,500.

As of November 30, 2022, 143,000 Class A shares have been issued to one previous owner of SDP and 19,019,000 Class A shares are to be issued.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

*b. Share based compensation*

The Company's Board of Directors determines, among other things, the eligibility of individuals to participate in the Option Plan and the term, vesting periods, and the exercise price of options granted under the Option Plan. The stock option vesting ranges over a 1 year to 10-year period. The outstanding stock options on November 30, 2022 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Grant date** | <br>**Exercise**<br>**price** | **Number of**<br>**options** | **Number of vested**<br>**options** | **Weighted Avg**<br>**Remaining**<br>**Life (years)** |
| March 28, 2014 | $2.13 | 5103 | 5103 | 1.33 |
| September 23, 2019 | 0.19 | 28155 | - | 1.82 |
| May 29, 2020 | 0.27 | 73700 | 73700 | 2.49 |
| August 18, 2020 | 0.19 | 73700 | 49133 | 7.72 |
| June 8, 2021 | 0.99 | 663300 | 221100 | 3.50 |
| June 8, 2021 | 0.86 | 1444520 | 481507 | 3.50 |
| June 8, 2021 | 0.86 | 225000 | 225000 | 3.50 |
| July 7, 2021 | 1.39 | 400000 | 133333 | 3.72 |
| December 6, 2021 | 0.65 | 1185400 | - | 4.02 |
| January 19, 2022 | 0.65 | 150000 | - | 4.14 |
| March 9, 2022 | 0.54 | 240000 | - | 4.27 |
| April 13, 2022 | 0.78 | 236700 | - | 4.37 |
| April 26, 2022 | 0.90 | 350000 | - | 4.41 |
| July 18, 2022 | 0.79 | 308650 | - | 4.63 |
| August 29, 2022 | 0.69 | 200000 | - | 4.66 |
| **Total** | $**0.82** | **5584228** | **1188876** | **3.91** |

---

---

| | | |
|:---|:---|:---|
| <br>A summary of the Company's options are as follows: | **Number of** <br>**Options** | **Weighted**<br>**Avg. Exercise Price** |
| **Balance as at February 28, 2021** | 2793380 | $**0.27** |
| Options exercised | (1605042) | 0.23 |
| Options expired and forfeited | (1345746) | - |
| Options issued | 4434440 | 0.75 |
| **Balance as at February 28, 2022** | **4277032** | $**0.78** |
| Options exercised | (28154) | 0.19 |
| Options exercised and forfeited | - | - |
| Options issued | 1335350 | 0.12 |
| **Balance as at November 30, 2022** | **5584228** | $**0.82** |

---

The Company recognized $380,937 and $1,248,709 of stock-based compensation for the three and nine months ended November 30, 2022, respectively ($292,492 and $757,792 for the three and nine months ended November 30, 2021, respectively).

On March 9, 2022, the Company issued 240,000 options to ten employees of SDP. The options vest over three years and are exercisable for a period of five years at an exercise price of $0.54 per option. The fair value of the options was estimated on the date of the grant at $0.53 per option using the Black-Scholes option pricing model with the following assumptions: expected volatility of 201%; expected dividend yield of 0%; risk-free interest rate of 1.50%; stock price of $0.54; and expected life of 5 years.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

On April 13, 2022, the Company issued 236,700 options to an officer of the Company. The options vest over three years and are exercisable for a period of five years at an exercise price of $0.78 per option. The fair value of the options was estimated on the date of the grant at $0.77 per option using the Black-Scholes option pricing model with the following assumptions: expected volatility of 210%; expected dividend yield of 0%; risk-free interest rate of 1.54%; stock price of $0.78; and expected life of 5 years.

On April 26, 2022, the Company issued 350,000 options to two employees of the Company. The options vest over three years and are exercisable for a period of five years at an exercise price of $0.90 per option. The fair value of the options was estimated on the date of the grant at $0.86 per option using the Black-Scholes option pricing model with the following assumptions: expected volatility of 214%; expected dividend yield of 0%; risk-free interest rate of 2.58%; stock price of $0.87; and expected life of 5 years.

On July 18, 2022, the Company issued 100,000 options to one employee of SDP, 58,650 options to eleven employees of Simbex, and 150,000 options to two outside consultants of the Company. The options vest over three years and are exercisable for a period of five years at an exercise price of $0.79 per option. The fair value of the options was estimated on the date of the grant at $0.78 per option using the Black-Scholes option pricing model with the following assumptions: expected volatility of 214%; expected dividend yield of 0%; risk-free interest rate of 1.21%; stock price of $0.79; and expected life of 5 years.

On August 29, 2022, the Company issued 200,000 options to an officer of the Company. The options vest over three years and are exercisable for a period of five years at an exercise price of $0.69 per option. The fair value of the options was estimated on the date of the grant at $0.67 per option using the Black-Scholes option pricing model with the following assumptions: expected volatility of 209%; expected dividend yield of 0%; risk-free interest rate of 1.40%; stock price of $0.68; and expected life of 5 years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*c. Warrants*

The outstanding warrants on November 30, 2022, are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Grant date** | <br>**Exercise**<br>**price** | **Number of**<br>**warrants** | **Number of vested**<br>**warrants** | **Weighted Avg**<br>**Remaining**<br>**Life (years)** |
| May 21, 2021 | 1.25 | 2121232 | 2121232 | 0.05 |
| May 21, 2021 | 0.47 | 421414 | 421414 | 0.05 |
| May 21, 2021 | 0.85 | 243675 | 243675 | 0.05 |
| November 11, 2021 | 0.86 | 199804 | 199804 | 0.95 |
| February 15, 2022 | 0.55 | 542431 | 542431 | 2.21 |
| February 15, 2022 | 0.70 | 7749000 | 7749000 | 2.21 |
| **Total** | $**0.79** | **11277556** | **11277556** | **1.65** |

---

A summary of the Company's warrants are as follows:

---

| | | |
|:---|:---|:---|
|  | **Number of** <br>**Warrants** | **Weighted**<br>**Avg. Exercise Price** |
| **Balance as at February 28, 2021** |  | $**-** |
| Warrants issued as part of finance deal | 10070036 | 0.70 |
| Broker warrants issued as part of finance deal | 1662337 | 0.09 |
| **Balance as at February 28, 2022** | **11732373** | $**0.79** |
| Warrants issued as part of finance deal |  |  |
| Broker warrants issued as part of finance deal |  |  |
| Broker warrants exercised | (454817) |  |
| **Balance as at November 30, 2022** | **11277556** | $**0.80** |

---

During the three and nine months ended November 30, 2022, no additional warrants were issued (February 28, 2022 - 10,070,036 warrants and 1,662,337 broker warrants were issued)

On May 4, 2022, 454,817 shares of common stock were issued on the exercise of 454,817 broker share purchase warrants at an exercise price of $0.4749 per share. Proceeds received from this exercise totaled $215,953.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

**14. Related party transactions**

The Company's transactions with related parties were carried out on normal commercial terms and in the ordinary course of the Company's business. Other than disclosed elsewhere in the Company's unaudited interim condensed consolidated financial statements, related party transactions are as follows.

---

| | | |
|:---|:---|:---|
|  | **For the nine months ended** | **For the nine months ended** |
|  | **November 30, 2022** | **November 30, 2021** |
| Salaries and short-term benefits | $764624 | $104062 |
| Stock based compensation | 707605 | 535603 |
| **Total** | $**1472229** | $**639665** |

---

Salary, allowance and other include salary, consulting fees, car allowance, vacation pay, bonus and other allowances paid or payable to a shareholder, directors, and executive officers of the Company. Stock based compensation are to the directors and executive officers of the Company (Note 13).

**15. Capital management**

The Company's objectives when managing capital are to: (a) maintain financial flexibility in order to preserve its ability to meet financial obligations and continue as a going concern; (b) maintain a capital structure that allows the Company to finance its growth using internally generated cash flow and debt capacity; and (c) optimize the use of its capital to provide an appropriate investment return to its shareholders commensurate with risk.

The Company's financial strategy is formulated and adapted according to market conditions in order to maintain a flexible capital structure that is consistent with its objectives and the risk characteristics of its underlying assets.

The Company manages its capital structure and may make adjustments to it in light of changes in economic conditions and the risk characteristics of its underlying assets. To maintain or adjust its capital structure, the Company may, from time to time, change the amount of dividend paid to shareholders, return capital to shareholders by way of normal course issuer bid, issue new shares, or reduce liquid assets to repay other debt.

**16. Net loss per share**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **Three months ended** |  | **Nine months ended** |
|  | **November 30, 2022** | **November 30, 2021** | **November 30, 2022** | **November 30, 2021** |
| Net loss | $(1528597) | $(1503697) | $(14326895) | $(3223268) |
| Weighted average number of Common and Class A shares | 55145538 | 44790162 | 54585045 | 41480296 |
| Net loss per share from operations |  |  |  |  |
| Basic | (0.03) | (0.03) | (0.26) | (0.08) |
| Diluted | (0.03) | (0.03) | (0.26) | (0.08) |

---

**17. Operating expenses**

General and administrative expenses include stock-based compensation of $380,937 and $1,248,709 for three and nine months ended November 30, 2022, respectively ($292,492 and $757,792 for the three and nine months ended November 30, 2021, respectively), as well as rent and facility costs, professional fees, research and development, public company expenses, insurance, and other general expenses.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

**18**. **Transaction costs including legal, financial, audit, US, and Canadian regulatory costs**

The Company incurred costs associated with the Change of Business transaction, due diligence of acquisition targets, financing costs, US regulatory costs and the associated accounting and regulatory costs. While these costs are crucial to future operations, they do not represent regular operational costs of the business. The Company presents these costs separately to better allow investors to evaluate the operational status of the Company independently of financing, regulatory and other transaction focused expenses, which were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | **Three months ended** |  | **Nine months ended** |
|  | **November 30,<br>**2022** | **November 30,**<br>**2021** | **November 30,** <br>**2022** | **November 30,** <br>**2021** |
| Consulting and professional fees | $557388 | $202455 | $1330910 | $1243042 |
| General expenses | 497214 | 842000 | 1072375 | 1026881 |
| **Transaction costs** | $**1054602** | $**1044455** | $**2403285** | $**2269923** |

---

**19. Cash and cash equivalents**

Cash represents bank deposits at financial institutions with high credit rating. Cash equivalents represent short-term, highly liquid investments, which are readily convertible to cash and have maturities of 90 days or less at time of purchase. As of November 30, 2022, there are no cash equivalents presented on the unaudited interim condensed consolidated balance sheet (February 28, 2022- $nil).

**20. Contingencies**

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of November 30, 2022, there are no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's operations. There are also no proceedings in which any of the Company's directors, officers or affiliates is an adverse party or has a material interest adverse to the Company's interest.

Other than the line of credit and debt disclosed in Note 11, the Company does not have any other financial commitments or contingencies.

------

**SALONA GLOBAL MEDICAL DEVICE CORPORATION**<br>**Notes to the Unaudited Interim Condensed Consolidated Financial Statements** **For the three and nine months ended November 30, 2022, and 2021**<br> **(In Canadian Dollars, unless otherwise stated)**

**21. Subsequent Events**

On December 15, 2022, the Company announced its intention to focus on listing on the Nasdaq Capital Market ("Nasdaq") in 2023. As a first step, the Company has changed its fiscal year end to December 31, 2022, with the aim of preparing for a U.S. listing.

On January 10, 2023, 104,850 Class A shares were exchanged for 104,850 common shares in the Company at a price of $0.44 per share. No cash was received as part of this issuance.

On January 13, 2023, the Company entered into an asset-based loan (ABL). The ABL is with a financial institution whereby the Company, through its subsidiaries, may borrow up to US$5,500,000. Borrowings' bear interest at 6% or prime +0.75% per annum, whichever is greater. The balance will be secured by the receivables of the Company's subsidiaries. The loan is not subject to any financial covenants.

**ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*As used in this Quarterly Report on Form 10-Q, the terms "the Company," "us," "our," the "Company" and "Salona" mean Salona Global Medical Device Corporation (a corporation incorporated under the laws of the Province of British Columbia formerly known as Brattle Street Investment Corp.) and its subsidiaries (unless the context indicates a different meaning).*

**Cautionary Note Regarding Forward-Looking Statements**

The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and related notes. This quarterly report, including, without limitation, statements under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations," includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "potential," "projects," "predicts," "continue," or "should," or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, economic and competitive conditions, the effects of the COVID 19 pandemic, regulatory changes and other uncertainties, the general expansion of its business, and other statements which are not statements of current or historical facts.

The forward-looking statements contained in this quarterly report are based on the Company's current expectations and beliefs concerning future developments and their potential effects on the Company. Future developments affecting us may not be those that the Company have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading "Risk Factors" in this Report as well as in the Company's Annual Report on Form 10-K for the year ended February 28, 2022, all of which are difficult to predict. Should one or more of these risks or uncertainties materialize or should any of these assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described under "Risk Factors" may not be exhaustive.

------

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition and liquidity, and developments in the industry in which it operates may differ materially from those made in or suggested by the forward-looking statements contained in this Report. In addition, even if the Company's results or operations, financial condition and liquidity, and developments in the industry in which it operates are consistent with the forward-looking statements contained in this Report, those results or developments may not be indicative of results or developments in subsequent periods.

**Non-GAAP Measures**

Throughout this management discussion and analysis, management uses a number of financial measures to assess its performance, and these are intended to provide additional information to investors concerning the Company. Some of these measures, including net profit (loss) from operations and Adjusted EBITDA (i) are not calculated in accordance with Generally Accepted Accounting Principles (GAAP), which are based on the United States Generally Accepted Accounting Principles (U.S. GAAP), (ii) are not defined by GAAP, and (iii) do not have standardized meanings that would ensure consistency and comparability between companies using these measures. Readers are cautioned that the disclosure of these items is meant to add to, and not replace, the discussion of financial results as determined in accordance with U.S. GAAP. The Company's presentation of this financial measure may not be comparable to similarly titled measures used by other companies The primary purpose of these non-GAAP measures is to provide supplemental information that may prove useful to investors who wish to consider the impact of certain non-cash or uncontrollable items on its operating performance and who wish to separate revenues and related costs associated with client acquisition that may not be ongoing.

Financial information presented in this Report is presented in **Canadian dollars,** unless otherwise indicated. Unless otherwise indicated, all references to years are to the Company's fiscal year ended on the last calendar day of February.

**Acquisition Pipeline**

On March 11, 2021, the Company completed a Change of Business, as defined by the TSX Venture Exchange, to become an acquisition-oriented medical device company with plans to achieve scale through further acquisitions and organic growth. The Company presently intends to operate in the recovery science market, including post-operative pain, wound care and other markets serving the aging population in the United States.

On May 21, 2021, the Company acquired South Dakota Partners Inc. ("SDP"). SDP operates a large state-of-the-art production facility located in the State of South Dakota currently producing proprietary and white label medical devices for pain management, cold and hot therapy, NMES, PEMF and ultrasound. Information relating to SDP contained in this Report covers the entire three- and nine-months ended November 30, 2022.

On September 30, 2021, the Company acquired Simbex, LLC ("Simbex"), an IP-based business that has a portfolio of several revenue and royalty generating products ranging from wearable technology to products for physical stability as well as expertise in development and design of many medical devices on the market it has innovated over the past several years. Information relating to Simbex contained in this Report covers the entire three- and nine-months ended November 30, 2022.

------

On November 29, 2021, the Company acquired the customer lists, sales orders and supply agreements, and related sales channel and intellectual property assets of ALG-Health, LLC ("ALG"), a business engaged in the selling medical devices and supplies to small, independent hospitals, group purchasing organizations, medical offices and clinics, in exchange for nonvoting securities of ALG Health Plus which are exchangeable for up to a maximum of 21,000,000 nonvoting Class A shares of the Company subject to the achievement of certain revenue and EBITDA targets. In connection with the transaction, its subsidiary ALG Health Plus entered into an exclusive supply agreement with ALG. Information relating to ALG contained in this Report covers the entire three and nine months ended November 30, 2022.

On March 11, 2022, the Company acquired Mio-Guard, LLC, ("Mio-Guard") a business engaged in medical device sales and marketing serving the Midwest United States. Mio-Guard has sold into the athletic training, physical therapy and orthopedics markets for sports medicine products. Mio-Guard has over fifty sales representatives in the United States with a focus on the Midwest, South and Central United States and long-standing relationships with institutions ranging from high school to college to professional athletics. . Information relating to Mio-Guard contained in this Report covers substantially all of the three- and nine-months ended November 30, 2022.

On September 23, 2022, the Company acquired DaMar Plastics Manufacturing Inc. ("DaMar"), a business engaged in designing, producing and selling specialty plastics in several markets including the medical device market. With over 50 years in business, DaMar currently provides the medical and consumer industries with precision plastic molding technology. The acquisition builds upon the Company's strategy to create a fully integrated global medical device company and adds precision plastics technology capabilities to the Company. The addition of DaMar Plastics to Salona Global is projected to add $6.6 million of revenue annually with gross profit margins of approximately 45%. Information relating to DaMar contained in this Report covers the period since acquisition (from September 23, 2022 through November 30, 2022).

On December 15, 2022, the Company announced its intention to focus on listing on the Nasdaq Capital Market ("Nasdaq") in 2023. As a first step, the Company has changed its fiscal year end to December 31, 2022, with the aim of preparing for a U.S. listing.

Additionally, the Company's management team has a pipeline of small, privately held, stand-alone and bolt-on medical device companies targeted for acquisition in the highly fragmented global market for injury, surgical prevention, rehabilitation and recovery for the aging population throughout the continuum of care, which fall into one of three primary categories:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Private smaller medical device companies struggling with sufficient capitalization and operational expertise to fully realize the value of their intellectual property;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Niche players that succeed in developing a handful of quality products often turn to larger listed companies that do not allow ownership to participate in the upside of including their device in a larger company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Smaller U.S.-listed companies that lack liquidity and coverage to offer sufficient upside to vendors.

The Company believes it is the well positioned to offer acquisition targets upside through stock and cash acquisitions with a liquid TSXV listing.

The Company intends to acquire any identified medical device targets using a structure similar to its prior acquisitions. It is intended that potential targets would primarily or solely receive Company equity as consideration for the potential acquisition rather than cash, which would reduce its requirement for additional capital. Additionally, to date, discussions are most advanced with targets that are operationally cash flow positive, which may enhance the Company's ability to borrow for additional capital needs.

**Selected Financial Information**

The Company uses Adjusted EBITDA, as calculated below, to assess the financial health of its acquisitions and determine the overall potential of its business not including transaction costs and other activities associated with the ongoing growth strategy of the Company. Adjusted EBITDA is calculated as net loss less interest, taxes, depreciation, amortization, stock-based compensation, foreign exchange gain, change in fair value of contingent consideration, and transaction costs.

------

**Revenues**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **2022 vs 2021** | **2022 vs 2021** | **Nine months ended** | **Nine months ended** | **2022 vs. 2021** |  |
|  | November 30,<br>2022 | November 30,<br>2021 | $ Change | % Change | November 30,<br>2022 | November 30,<br>2021 | $ Change | % Change |
| **Revenue** | $10547652 | $5286702 | $5260950 | 100% | $30640439 | $9850915 | $20789524 | 211% |
| **Gross Margin** | 3495160 | 1662636 | 1832524 | 110% | 10165938 | 3073782 | 7092156 | 231% |
| **Adjusted EBITDA** | $(159717) | $302536 | $(462253) | (153%) | $1267687 | $577357 | $690330 | 120% |

---

**Adjusted EBITDA** 

Adjusted EBITDA is calculated as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Nine months ended** | **Nine months ended** |  |
|  | **November 30,** <br>**2022** | **November 30,** <br>**2021** | **November 30,** <br>**2022** | **November 30,**<br>**2021** |
| **Adjusted EBITDA** | $(159717) | $302536 | $1267687 | $577357 |
| Less: Stock Based Compensation | (380937) | (292492) | (1248709) | (757792) |
| **Net loss before the undernoted** | **(540654**) | **10044** | **18978** | **(180435**) |
| Amortization of intangible asset | (301990) | (165552) | (786842) | (244340) |
| Depreciation of property and equipment | (147622) | (65458) | (292476) | (131414) |
| Amortization of right-of-use asset | (285967) | (67817) | (508185) | (106700) |
| Interest Expense | (226573) | (121518) | (508649) | (265602) |
| Foreign exchange loss | (13703) | (48934) | (13471) | (38397) |
| Change in fair value of earn-out consideration |  |  | (2451600) |  |
| Change in fair value of contingent consideration | 980730 |  | (7532300) |  |
| Gain on share for debt settlement |  |  |  | 15538 |
| Transaction costs including legal, financial, audit and US & Canadian regulatory expenses | (1054602) | (1044455) | (2403285) | (2269923) |
| Current income tax expense | (11754) | (7) | (41786) | (1995) |
| Deferred income tax recovery | 73538 | - | 192721 | - |
| **Net Loss** | $**(**1528597)** | $**(1503697)** | **$(14326895)** | $**(3223268)** |

---

------

**RESULTS OF OPERATIONS`**

**Revenues**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **2022 vs 2021** | **2022 vs 2021** | **Nine months ended** | **Nine months ended** | **2022 vs. 2021** | **2022 vs. 2021** |
|  | November 30,<br>2022 | November 30,<br>2021 | $ Change | % Change | November 30,<br>2022 | November 30,<br>2021 | $ Change | % Change |
| **Revenue** | $10547652 | $5286702 | $5260950 | 100% | $30640439 | $9850915 | $20789524 | 211% |

---

Since the acquisition of SDP on May 21, 2021, Simbex on September 30, 2021, Mio-Guard on March 11, 2022, DaMar on September 23, 2022, and the sales channel assets of ALG on November 28, 2021, the Company has continued generating sales revenue in line with each of their pre-COVID revenue figures and each continue to grow. From March 1, 2022, through November 30, 2022, the Company generated sales of $30,640,439.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **2022 vs 2021** | **2022 vs 2021** | **Nine months ended** | **Nine months ended** | **2022 vs. 2021** |  |
|  | November 30,<br>2022 | November 30,<br>2021 | $ Change | % Change | November 30,<br>2022 | November 30,<br>2021 | $ Change | % Change |
| **Cost of Revenue** |  |  |  |  |  |  |  |  |
| Direct service personnel | $1472850 | $953260 | $519590 | 55% | $4465024 | $1230443 | $3234581 | 263% |
| Direct material costs | 5269741 | 2431065 | 2838676 | 117% | 15146076 | 5306949 | 9839127 | 185% |
| Other direct costs | 309901 | 239741 | 70160 | 29% | 863401 | 239741 | 623660 | 260% |

---

Cost of revenue includes the Company's labor costs expended in the production of medical devices, and related expenses allocated directly to the production of medical devices, and its cost of actual materials used in the production process from March 1, 2022, through November 30, 2022. Cost of revenue also includes the purchase of trading goods and costs associated with contract service revenue. The ongoing issues with the global supply chain process caused by COVID-19 and other economic factors has impacted the Company's ability to source affordable components. While there can be no assurances, management believes that the negative impacts on the Company's sourcing of components will diminish as the global supply chain stabilizes.

*Amortization, Depreciation, Interest, Transaction Costs and Foreign Exchange Gain Change in fair value of earn-out and contingent consideration*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **2022 vs 2021** | **2022 vs 2021** | **Nine months ended** | **Nine months ended** | **2022 vs. 2021** |  |
|  | November 30,<br>2022 | November 30,<br>2021 | $ Change | % Change | November 30,<br>2022 | November 30,<br>2021 | $ Change | % Change |
| Amortization of intangible assets | $(301990) | $(165552) | $(136438) | 82% | $(786842) | $(244340) | $(542502) | 222% |
| Depreciation of property and equipment | (147622) | (65458) | (82164) | 126% | (292476) | (131414) | (161062) | 123% |
| Amortization of right-of-use assets | (285967) | (67817) | (218150) | 322% | (508185) | (106700) | (401485) | 376% |
| Interest expense | (226573) | (121518) | (105055) | 86% | (508649) | (265602) | (243047) | 92% |
| Foreign exchange loss | (13703) | (48934) | 35231 | (72%) | (13471) | (38397) | 24926 | (65%) |
| Transaction costs including legal, financial,<br>audit, US & Canadian Regulatory | (1054602) | (1044455) | (10147) | 1% | (2403285) | (2269923) | (133362) | 6% |
| Change in fair value of earn-out consideration |  |  |  | -% | (2451600) |  | (2451600) | 100% |
| Change in fair value of contingent consideration | 980730 |  | 980730 | 100% | (7532300) |  | (7532300) | 100% |

---

------

Amortization of intangible assets reflects the amortization of intangible assets such as trademarks, non-compete agreement, intellectual property, and customer base. The Company depreciates property and equipment across their useful lives. While there can be no assurances, the Company expects depreciation of property and equipment and of right of use asset and interest expense to increase as the Company continues to grow its balance sheet through acquisitions.

The change in fair value of earnout consideration represents the increase in fair value of SDP's 19,162,000 earnout shares on May 31, 2022, the date of issuance. The change in fair value of the contingent consideration represents the obligations resulting from the Simbex, Health Plus, DaMar, and Mio-Guard acquisitions. The company assesses its potential obligations related to these commitments during the quarter and fair values them accordingly.

Transaction costs include legal, financial, audit, US and Canadian regulatory expenses and other fees incurred in connection with the Change of Business transaction, the SDP, Simbex, Mio-Guard, DaMar and ALG acquisitions, due diligence of acquisition targets, financing costs, US regulatory costs, and associated accounting and other costs. While these costs are necessary, they are not operational expenses of the business.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **2022 vs 2021** | **2022 vs 2021** | **Nine months ended** | **Nine months ended** | **2022 vs. 2021** |  |
|  | November 30,<br>2022 | November 30,<br>2021 | $ Change | % Change | November 30,<br>2022 | November 30,<br>2021 | $ Change | % Change |
| Foreign currency translation gain (loss) | $(79919) | $112505 | $(192424) | (171%) | $(37967) | $128506 | $(166473) | (130%) |

---

Since the Company operates in the United States, it is exposed to foreign currency risk. Management is unable to effectively predict swings in the foreign exchange value of the U.S. Dollar against the Canadian Dollar. When currency is moved between denominations, a gain or loss may be realized which management is unable to accurately predict.

**Liquidity and Capital Resources**

The Company funds its operations through cash from operations and asset-based loans secured by subsidiary inventory and accounts receivable from third parties. In February 2022, the Company completed a private placement of 7,749,000 units (the "Units") at $0.55 per Unit (consisting of one common share and one warrant to purchase one common share) for gross proceeds of approximately $4.26 million. As of November 30, 2022, the Company had $3,138,860 of cash and cash equivalents, which was a decrease of $4,918,240 from the balance as of February 28, 2022. During the nine months ended November 30, 2022, the Company generated $215,953 from the exercise of 454,817 broker share purchase warrants. During the nine months ended November 30, 2022, the Company generated $5,329 from the exercise of 28,154 of stock options.

***Long Term Debt***

On June 9, 2021, the Company's subsidiary SDP entered into a $7,294,320 (US$5,400,000) revolving loan facility with a third-party financial institution, which refinanced their existing revolving loan facility and other notes. All amounts outstanding under the $6,162,803 revolving loan facility bear interest at the greater of 4% or prime plus 0.75% per annum, and any accrued unpaid interest is payable monthly, with a maturity of August 1, 2023. The repayment obligations under the $7,294,320 facility are secured by a first priority lien on substantially all of the assets of SDP and are not guaranteed by the Company or any other subsidiary. In addition, on June 9, 2021, SDP issued a secured promissory note in the principal amount of $982,200 (US$750,000) which evidenced the refinancing of two outstanding loans. The note bears interest at the greater of 6% or prime rate plus 2.75% per annum. Principal and accrued but unpaid interest due on the note are payable monthly in equal installments over a 36-month period, and the repayment obligations under the note are secured by a lien on substantially all of the assets of SDP. As of November 30, 2022, the Company had long term debt of $781,228 related to the above note, as compared to $856,119 on February 28, 2022.

On January 13, 2023, the Company entered into an asset-based loan (ABL). The ABL is with a financial institution whereby the Company, through its subsidiaries, may borrow up to US$5,500,000. Borrowings' bear interest at 6% or prime +0.75% per annum, whichever is greater. The balance will be secured by the receivables of the Company's subsidiaries. The loan is not subject to any financial covenants.

***Cash Flows***

The following table is a summary of the Company's cash flows for the nine months ended November 30, 2022, and November 30, 2021:

---

| | | |
|:---|:---|:---|
|  | **November 30,** <br>**2022** | **November 30,** <br>**2021** |
| Net cash used in operating activities | $(87964) | $(1336020) |
| Net cash used in investing activities | (5322020) | (4142266) |
| Net cash provided by (used in) financing activities | 560708 | (1092067) |
| Net decrease in cash and cash equivalents and restricted cash | (4849276) | (6570353) |

---

------

***Net Cash Used in Operating Activities***

During the period ended November 30, 2022, $87,964 was used for operating activities (compared to $1,336,020 used for operating activities for the period ended November 30, 2021). This cash flow was used primarily to improve the back office and administrative capacity of the Company, fund certain design and development projects, make expenditures to expand the market for certain products, support efforts to reduce supply chain constraints and increase productivity in all aspects of the business.

***Net Cash Used in Investing Activities***

During the period ended November 30, 2022, $5,322,021 was used in investing activities, compared to $4,142,266 that was used in the period ended November 30, 2021. The use of cash flow reflects the acquisition of DaMar of $4,318,236, the acquisition of Mio-Guard of $589,340, and the acquisition new property and equipment of $339,588. It also includes the purchase of intangible assets including intellectual property of $278,202.

***Net Cash Provided by (Used in) Financing Activities***

During the period ended November 30, 2022, $560,708 was provided through financing activities, compared to $1,092,067 used during the period ended November 30, 2021. The cash provided during the period ended November 30, 2022, was primarily from proceeds from the line of credit, net proceeds received from ALG-Health, and proceeds from the exercise of broker warrants, offset by lease payments. The cash used in in the period ended November 30, 2021, was primarily for the repayment of long-term debt, offset partially by the proceeds from the line of credit and proceeds from the exercise of stock options.

The Company currently intends to satisfy its short- and long-term liquidity requirements through its existing cash, current assets and cash flow from operating activities.

To date, the Company has not paid a cash dividend on its capital stock. Any future determination to pay cash dividends will be at the discretion of the Company's Board of Directors (the "Board") and will depend upon the Company's financial condition, operating results, capital requirements and such other factors as the Board deems relevant.

**Off-Balance Sheet Arrangements**

The Company did not have any off-balance sheet arrangements during the periods covered by this Report.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.**

The Company does not ordinarily hold market risk sensitive instruments for trading purposes and currently does not have any investments in marketable securities, which would expose it to market risks.

**Interest Rate Risk**

As part of its ongoing operations, the Company is exposed to interest rate fluctuations on borrowings. See "Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations -Liquidity and Capital Resources - Long Term Debt". As of November 30, 2022, the Company has two variable rate debt instruments outstanding that are impacted by changes in interest rates. The interest rate of the Company's revolving loan facility is equal to the 4% or prime plus 0.75% per annum, and the interest rate of the Company's secured promissory note is equal to the greater of 6% or prime rate plus 2.75% per annum.

------

There is no assurance that interest rates will increase or decrease over the Company's next fiscal year or that an increase will not have a material adverse effect on its operations.

**Foreign Currency Risk**

The Company receives and makes payments in U.S. currency and accordingly is subject to the financial risks associated with changes in the exchange rate between U.S. currency and Canadian currency. The Company has not entered into any hedge arrangements intending to mitigate this exchange rate risk, and there is no assurance that the exchange rates will not fluctuate over the next fiscal year or that such fluctuations will not have a material adverse effect on the Company's operations.

**ITEM 4. CONTROLS AND PROCEDURES**

**Evaluation of Disclosure Controls and Procedures**

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its reports filed with the U.S. Securities and Exchange Commission (the "SEC") is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

As of November 30, 2022, an evaluation was performed under the supervision and with the participation of management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of its disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) to the Securities Exchange Act of 1934). Based on that evaluation, management, including our Chief Executive Officer concluded as of November 30, 2022, the Company's disclosure controls and procedures were not effective as required under Rules 13a-15(e) and 15d-15(e) under the Exchange Act.

**Changes in Internal Control Over Financial Reporting**

During the period covered by this Report, the Company has not made any change to its internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, its internal control over financial reporting.

**PART II. OTHER INFORMATION**

**ITEM 1. LEGAL PROCEEDINGS**

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of its business. The Company is not currently a party to any legal proceedings the outcome of which, if determined adversely to the Company, would individually or in the aggregate have a material adverse effect on its business, financial condition, results of operations or prospects.

------

**ITEM 1A. RISK FACTORS**

There have been no material changes to the risk factors included in "Part I. Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended February 28, 2022, and "Part II. Item 1A. Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended May 31, 2022.

------

**ITEM 6. EXHIBITS**

The following exhibits are filed with this Report:

---

| | |
|:---|:---|
| Exhibit | Description |
| [31.1](exhibit31-1.htm) | [Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.](exhibit31-1.htm) |
| [31.2](exhibit31-2.htm) | [Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.](exhibit31-2.htm) |
| [32.1](exhibit32-1.htm) | [Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit32-1.htm) |
| [32.2](exhibit32-2.htm) | [Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit32-2.htm) |
| 101.INS | Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document |
| [101.SCH](sgmd-20221130.xsd) | [Inline XBRL Taxonomy Extension Schema Document](sgmd-20221130.xsd) |
| [101.CAL](sgmd-20221130_cal.xml) | [Inline XBRL Taxonomy Extension Calculation Linkbase Document](sgmd-20221130_cal.xml) |
| [101.DEF](sgmd-20221130_def.xml) | [Inline XBRL Taxonomy Extension Definition Linkbase Document](sgmd-20221130_def.xml) |
| [101.LAB](sgmd-20221130_lab.xml) | [Inline XBRL Taxonomy Extension Label Linkbase Document](sgmd-20221130_lab.xml) |
| [101.PRE](sgmd-20221130_pre.xml) | [Inline XBRL Taxonomy Extension Presentation Linkbase Document](sgmd-20221130_pre.xml) |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | |
|:---|:---|
|  | SALONA GLOBAL MEDICAL DEVICE CORPORATION |
|  | By:&nbsp;&nbsp;&nbsp;&nbsp; /s/ Luke Faulstick |
|  | Name: Luke Faulstick<br>Title: Chief Executive Officer (principal executive officer and duly authorized signatory for the registrant) |
| Date: January 17, 2023 |  |
|  | SALONA GLOBAL MEDICAL DEVICE CORPORATION |
|  | By:&nbsp;&nbsp;&nbsp;&nbsp; /s/ Dennis Nelson |
|  | Name: Dennis Nelson<br>Title: Chief Financial Officer (principal financial officer and duly authorized signatory for the registrant) |
| Date: January 17, 2023 |  |

---

------

## Exhibit 31.1

------

**Exhibit 31.1**

**CERTIFICATION**

I, Luke Faulstick, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Salona Global Medical Device Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: January 17, 2023 | /s/ Luke Faulstick |
|  | Luke Faulstick |
|  | Chief Executive Officer |
|  | (Principal Executive Officer) |

---

------

## Exhibit 31.2

------

**Exhibit 31.2**

**CERTIFICATION**

I, Dennis Nelson, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Salona Global Medical Device Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: January 17, 2023 | /s/ Dennis Nelson |
|  | Dennis Nelson |
|  | Chief Financial Officer |
|  | (Principal Financial Officer) |

---

------

## Exhibit 32.1

------

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**<br>**18 U.S.C. SECTION 1350,**<br>**AS ADOPTED PURSUANT TO**<br>**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Luke Faulstick, the Chief Executive Officer of Salona Global Medical Device Corporation (the "Registrant"), hereby certifies that, to the best of his knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Registrant's Quarterly Report on Form 10-Q for the period ended November 30, 2022, to which this Certification is attached as Exhibit 32.1 (the "Periodic Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Registrant at the end of the period covered by the Periodic Report and results of operations of the Registrant for the periods covered by the Periodic Report.

---

| | |
|:---|:---|
| Date: January 17, 2023  | /s/ Luke Faulstick |
|  | Luke Faulstick |
|  | Chief Executive Officer |
|  | (Principal Executive Officer) |

---

------

## Exhibit 32.2

------

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**<br>**18 U.S.C. SECTION 1350,**<br>**AS ADOPTED PURSUANT TO**<br>**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Dennis Nelson, the Chief Financial Officer of Salona Global Medical Device Corporation (the "Registrant"), hereby certifies that, to the best of his knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Registrant's Quarterly Report on Form 10-Q for the period ended November 30, 2022, to which this Certification is attached as Exhibit 32.1 (the "Periodic Report"), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Registrant at the end of the period covered by the Periodic Report and results of operations of the Registrant for the periods covered by the Periodic Report.

---

| | |
|:---|:---|
| Date: January 17, 2023  | /s/ Dennis Nelson |
|  | Dennis Nelson |
|  | Chief Financial Officer |
|  | (Principal Financial Officer) |

---

------